<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1526</journal-id><journal-id journal-id-type="pmc-domain">frontmicrobio</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7193113</article-id><article-id pub-id-type="pmcid-ver">PMC7193113.1</article-id><article-id pub-id-type="pmcaid">7193113</article-id><article-id pub-id-type="pmcaiid">7193113</article-id><article-id pub-id-type="pmid">32390971</article-id><article-id pub-id-type="doi">10.3389/fmicb.2020.00658</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tse</surname><given-names initials="LV">Longping V.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/277623/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meganck</surname><given-names initials="RM">Rita M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Graham</surname><given-names initials="RL">Rachel L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/911681/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baric</surname><given-names initials="RS">Ralph S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Epidemiology, The University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Curriculum in Genetics and Molecular Biology, The University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lu Lu, Fudan University, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Jasper Fuk Woo Chan, The University of Hong Kong, Hong Kong; Susan Baker, Loyola University Chicago, United States</p></fn><corresp id="c001">*Correspondence: Ralph S. Baric, <email>rbaric@email.unc.edu</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">350391</issue-id><elocation-id>658</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>04</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>08</day><month>05</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-11 19:25:13.993"><day>11</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 Tse, Meganck, Graham and Baric.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Tse, Meganck, Graham and Baric</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmicb-11-00658.pdf"/><abstract><p>Emerging coronaviruses (CoV) are constant global public health threats to society. Multiple ongoing clinical trials for vaccines and antivirals against CoVs showcase the availability of medical interventions to both prevent and treat the future emergence of highly pathogenic CoVs in human. However, given the diverse nature of CoVs and our close interactions with wild, domestic and companion animals, the next epidemic zoonotic CoV could resist the existing vaccines and antivirals developed, which are primarily focused on Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS CoV). In late 2019, the novel CoV (SARS-CoV-2) emerged in Wuhan, China, causing global public health concern. In this review, we will summarize the key advancements of current vaccines and antivirals against SARS-CoV and MERS-CoV as well as discuss the challenge and opportunity in the current SARS-CoV-2 crisis. At the end, we advocate the development of a &#8220;plug-and-play&#8221; platform technologies that could allow quick manufacturing and administration of broad-spectrum countermeasures in an outbreak setting. We will discuss the potential of AAV-based gene therapy technology for <italic toggle="yes">in vivo</italic> therapeutic antibody delivery to combat SARS-CoV-2 outbreak and the future emergence of severe CoVs.</p></abstract><kwd-group><kwd>coronavirus (CoV)</kwd><kwd>vaccine</kwd><kwd>antivirals</kwd><kwd>adeno-associate virus</kwd><kwd>passive immunization strategy</kwd><kwd>MERS- and SARS-CoV</kwd><kwd>2019 nCoV</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn001">AI108197</award-id><award-id rid="cn001">AI110700</award-id><award-id rid="cn001">AI132178</award-id><award-id rid="cn001">AI149644</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="289"/><page-count count="26"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p>The zoonotic transmission and subsequent adaptation to humans of emerging RNA viruses is a global public health concern. In the 21st century alone, coronaviruses (CoV) have been responsible for two separate endemics, the <underline>s</underline>evere <underline>a</underline>cute <underline>r</underline>espiratory <underline>s</underline>yndrome (SARS) and <underline>M</underline>iddle <underline>E</underline>ast <underline>R</underline>espiratory <underline>S</underline>yndrome (MERS) CoVs (<xref rid="B61" ref-type="bibr">de Wit et al., 2016</xref>). In late Dec 2019, a novel SARS-like CoV designated 2019 nCoV emerged in Wuhan China, causing &gt; 60,000 cases and over 1350 deaths in an ongoing epidemic (<xref rid="B105" ref-type="bibr">Hui et al., 2020</xref>). Other highly pathogenic threat viruses that have emerged in the 21st century include influenza viruses, Ebola viruses, flaviviruses and paramyxoviruses (<xref rid="B155" ref-type="bibr">Mackenzie and Jeggo, 2013</xref>). The high mutation and recombination rate of RNA viruses drives the emergence of new viral strains that can rapidly adapt to new and changing ecologies (<xref rid="B68" ref-type="bibr">Drake and Holland, 1999</xref>; <xref rid="B131" ref-type="bibr">Lauring and Andino, 2010</xref>). Furthermore, industrialization, globalization and traditional cultural habits potentiate the likelihood of zoonotic transmission and facilitate the spread of viruses in the human population. While new outbreaks from emergent viruses are inevitable, scientists, epidemiologists, and the health care industry are racing to develop new technologies to better predict and minimize the impact of an outbreak by employing global viral surveillance programs and developing vaccines and antivirals (<xref rid="B144" ref-type="bibr">Lipkin and Firth, 2013</xref>). A major challenge of vaccine and antiviral development is the elusive nature of the emerging viruses, which oftentimes emerge from highly heterogeneous populations of virus strains that circulate in animal reservoirs (<xref rid="B131" ref-type="bibr">Lauring and Andino, 2010</xref>). Therefore, to prepare for future outbreaks, vaccines and antivirals will need to be both potent and broadly effective against multiple potential emerging viruses within and across virus families. Additionally, in order to control and prevent viral spread, treatments must be readily available to affected populations and have a fast response time. In this review, we will focus our discussion on the challenges, as well as current development, of vaccines and antivirals for SARS-CoV and MERS-CoV. At the end, we will also discuss the potential use of AAV-based gene therapy as a quick response to prevent and treat emerging viral infections in the current SARS-CoV-2 and future outbreak situations.</p><sec id="S1.SS1"><title>Endemic and Emerging Coronaviruses</title><p>Coronaviruses are a diverse group of positive-stranded RNA viruses which infect a wide range of animals from birds to mammals, causing a variety of diseases (<xref rid="B193" ref-type="bibr">Perlman and Netland, 2009</xref>; <xref rid="B261" ref-type="bibr">Woo et al., 2009</xref>; <xref rid="B189" ref-type="bibr">Peck et al., 2015</xref>). Based on sequence identity of the spike protein or the non-structural proteins (nsp), CoVs are classified into four different sub-groups, <italic toggle="yes">alphacoronaviruses</italic>, <italic toggle="yes">betacoronaviruses</italic>, <italic toggle="yes">gammacoronaviruses</italic>, and <italic toggle="yes">deltacoronaviruses</italic> (<xref ref-type="fig" rid="F1">Figure 1</xref>). Human coronaviruses (hCoVs), such as 229E, OC43, NL-63 and HKU-1 are highly transmissible respiratory viruses which are responsible for around 10-20% of common cold cases annually (<xref rid="B161" ref-type="bibr">McIntosh et al., 1970</xref>; <xref rid="B33" ref-type="bibr">Cabe&#231;a et al., 2013</xref>). HCoV-related illness is often self-limited in immune competent individuals but may cause more severe upper and lower respiratory tract infections in the young and elderly population (<xref rid="B262" ref-type="bibr">Woo et al., 2005</xref>; <xref rid="B130" ref-type="bibr">Lau et al., 2006</xref>). In addition, highly pathogenic CoVs may emerge through zoonotic reservoirs. In the past two decades, SARS-CoV and MERS-CoV emerged from bats and spread to humans through intermediate hosts including civet cats and camels, respectively (<xref rid="B203" ref-type="bibr">Raj et al., 2014</xref>). SARS-CoV and MERS-CoV belong to the sub-groups 2b and 2c of the <italic toggle="yes">Betacoronavirus</italic> genus (<xref rid="B189" ref-type="bibr">Peck et al., 2015</xref>). The latest CoV outbreak is the SARS-CoV-2, a <italic toggle="yes">Betacoronavirus</italic> 2b which emerged from bats and spread to humans (<xref rid="B151" ref-type="bibr">Lu et al., 2020</xref>). The mortality rate of these viruses range from 10 to 40% but can exceed 50% in the elderly (<xref rid="B170" ref-type="bibr">Min et al., 2004</xref>; <xref rid="B136" ref-type="bibr">Li et al., 2005</xref>; <xref rid="B29" ref-type="bibr">Bolles et al., 2011b</xref>; <xref rid="B203" ref-type="bibr">Raj et al., 2014</xref>; <xref rid="B216" ref-type="bibr">Sharif-Yakan and Kanj, 2014</xref>; <xref rid="B263" ref-type="bibr">World Health Organization [WHO], 2018</xref>). The unusually high mortality rate is linked to disease progression leading to acute respiratory distress syndrome (ARDS) which causes hypoxemia, pulmonary edema, and infiltration of inflammatory immune cells in the lung (<xref rid="B33" ref-type="bibr">Cabe&#231;a et al., 2013</xref>; <xref rid="B89" ref-type="bibr">Gralinski and Baric, 2015</xref>). If unresolved, the diseases progress to late phase ARDS, leading to end-stage lung disease and death (<xref rid="B67" ref-type="bibr">Ding et al., 2003</xref>). Currently, no vaccines or antiviral drugs are approved to prevent or treat severe CoV infection.</p><fig id="F1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>Spike and nsp12 phylogeny of representative coronaviruses. The Spike <bold>(A)</bold> and nsp12 <bold>(B)</bold> protein sequences of selected coronaviruses were aligned and phylogenetically compared. Coronavirus genera are grouped by classic subgroup designations (1, 2a-d, 3, and 4). In the Spike tree in <bold>(A)</bold>, SADS-CoV is designated as 1* because of its distinctive grouping compared with more conserved proteins (e.g., nsp12, see <bold>(B)</bold>). Branches in each tree are labeled with consensus support values (in %). Sequences were aligned using free end gaps with the Blosum62 cost matrix, and the tree was constructed using the neighbor-joining method based on the multiple sequence alignment in Geneious Prime. Numbers following the underscores in each sequence correspond to the GenBank Accession number. The SARS-CoV-2 is highlighted in red. The radial phylogram was exported from Geneious and then rendered for publication using Adobe Illustrator CC 2020.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-11-00658-g001.jpg"/></fig></sec><sec id="S1.SS2"><title>The Challenge for Vaccine Development</title><p>The CoV <italic toggle="yes">S</italic>-protein is the major envelope glycoprotein and the main determinant of protective immunity. The <italic toggle="yes">S</italic>-protein is composed of two principle subunits, S1 and S2; S1 governs receptor binding and S2 is responsible for membrane fusion (<xref rid="B134" ref-type="bibr">Li, 2016</xref>). Similar to other class I fusion proteins, <italic toggle="yes">S</italic>-protein undergoes a major conformational change between pre-fusion and post-fusion which also presents different antigenic epitopes. While able to bind to both conformations, Abs targeting the post-fusion form are not necessary neutralizing; in contrast, Abs targeting the pre-fusion form of the <italic toggle="yes">S</italic>-protein correlate better with neutralization. In particular, vaccines and neutralizing antibodies (nAbs) which target the receptor binding domain (RBD) of the <italic toggle="yes">S</italic>-protein can effectively neutralize the virus (<xref rid="B285" ref-type="bibr">Zhu et al., 2007</xref>; <xref rid="B235" ref-type="bibr">Tang et al., 2014</xref>). However, due to high selective pressure and tropism determinants, <italic toggle="yes">S</italic>-protein is the most diverse region of CoV. For instance, the <italic toggle="yes">S</italic>-proteins from SARS-CoV and MERS-CoV share only 44% sequence identity (<xref rid="B113" ref-type="bibr">Kandeel, 2018</xref>). The majority of differences between <italic toggle="yes">S</italic>-proteins is in the S1 region, which is further separated into the N-terminal Domain (NTD) and RBD. The diverse nature of the RBD between SARS-CoV and MERS-CoV is reflected in the use of different entry receptors, either angiotensin I converting enzyme 2 (ACE2) or dipeptidyl peptidase 4 (DPP4), respectively (<xref rid="B135" ref-type="bibr">Li et al., 2003</xref>; <xref rid="B201" ref-type="bibr">Raj et al., 2013</xref>). The diversity of <italic toggle="yes">S</italic>-protein also renders vaccines and nAbs unlikely to be cross-protective between existing and emerging CoVs. Surveillance and experimental data have identified multiple animal SARS- and MERS-like CoVs that have significant diversity in <italic toggle="yes">S</italic>-protein and are able to replicate in human cells without adaptation (<xref rid="B164" ref-type="bibr">Menachery et al., 2015</xref>, <xref rid="B166" ref-type="bibr">2016</xref>; <xref rid="B152" ref-type="bibr">Luo et al., 2018</xref>). Once transmitted to human population, such variation between <italic toggle="yes">S</italic>-protein between the previous and the new emerging CoVs will pose a major challenge on the progress of vaccine development.</p></sec></sec><sec id="S2"><title>Criteria for Generating Effective Vaccine for CoVs</title><sec id="S2.SS1"><title>Vaccine Criteria for SARS and MERS-CoV Viruses</title><p>The surface glycoproteins are the main target for vaccine development. In CoV infection, Abs against <italic toggle="yes">S</italic>-protein were shown to be protective in multiple animal studies. Furthermore, in a passive immunization study in camel, the nAb level is directly correlated to lung pathology and survival (<xref rid="B281" ref-type="bibr">Zhao et al., 2015</xref>). As such, one of the main goals for CoV vaccines in humans is the ability to elicit a strong humoral immune response against the <italic toggle="yes">S</italic>-protein. Particularly, the pre-fusion form of the <italic toggle="yes">S</italic>-protein is an attractive target for Abs to confer protective immunity. In order to &#8220;lock&#8221; the <italic toggle="yes">S</italic>-protein in its antigenic optimal pre-fusion form, two mutations, V1060P and L1061P, were introduced into the MERS-CoV <italic toggle="yes">S</italic>-protein (<xref rid="B186" ref-type="bibr">Pallesen et al., 2017</xref>). The resulting MERS S-2P is able to elicit both RBD and non-RBD binding nAbs (<xref rid="B186" ref-type="bibr">Pallesen et al., 2017</xref>). The same strategy was also shown to work in the SARS-CoV-2 <italic toggle="yes">S</italic>-protein (<xref rid="B264" ref-type="bibr">Wrapp et al., 2020</xref>). Other structural proteins such as E and M and the nsp N also contribute to viral protection and clearance (<xref rid="B41" ref-type="bibr">Channappanavar et al., 2014</xref>; <xref rid="B283" ref-type="bibr">Zhao et al., 2016</xref>; <xref rid="B64" ref-type="bibr">Deng et al., 2018</xref>). Similarly to other respiratory viruses such as influenza, mucosal IgA plays a major role in disease protection and has a synergistic effect with IgG (<xref rid="B23" ref-type="bibr">Belshe et al., 2000</xref>; <xref rid="B196" ref-type="bibr">Plotkin, 2010</xref>). In order to elicit a strong mucosal IgA immunity, the route of vaccine administration is important. Studies have shown that intranasal inoculation of a recombinant RBD vaccine can elicit greater mucosal IgA production than intramuscular or subcutaneous injection (<xref rid="B153" ref-type="bibr">Ma et al., 2014a</xref>). However, the duration of mucosal antibodies is typically shorter lived than systemic IgG responses and the longest longitudinal study of MERS-CoV IgA responses ended after 6 months (<xref rid="B95" ref-type="bibr">Hapfelmeier et al., 2010</xref>; <xref rid="B153" ref-type="bibr">Ma et al., 2014a</xref>). In comparison, in a natural infection case study, SARS-targeting systemic memory B cells were present up to 6 years for SARS-CoV (<xref rid="B182" ref-type="bibr">Oh et al., 2012</xref>; <xref rid="B233" ref-type="bibr">Tang et al., 2019</xref>); and up to 34 months post infection for MERS-CoV (<xref rid="B188" ref-type="bibr">Payne et al., 2016</xref>). Another important consideration for SARS-CoV and MERS-CoV vaccination is the T cell response against the virus, specifically the N proteins, which is important for viral clearance (<xref rid="B282" ref-type="bibr">Zhao et al., 2010</xref>; <xref rid="B41" ref-type="bibr">Channappanavar et al., 2014</xref>). A study has shown that adoptive transfer of viral specific T-cells to SCID mice enhances survival and reduces lung titer after SARS-CoV infection (<xref rid="B282" ref-type="bibr">Zhao et al., 2010</xref>). Moreover, intranasal vaccination of N protein using the VEEV replicon system elicits CD4+ memory T-cells responses in the airway. Upon challenge, the airway CD4+ memory T cells secrete IFN-&#947;, which subsequently enhances the innate immune response as well as coordinates the CD8+ T cell priming and migration which protects mice from lethal disease, but not weight loss or virus titers under carefully controlled conditions (<xref rid="B283" ref-type="bibr">Zhao et al., 2016</xref>). Interestingly, Rag&#8722;/&#8722; mice are able to clear SARS-CoV infection, suggesting innate immunity is sufficient for viral clearance (<xref rid="B282" ref-type="bibr">Zhao et al., 2010</xref>). However, the mechanism of this viral clearance is still unknown. Another important aspect of emerging CoV vaccine is the breadth of protection. As mentioned previously, the antigenic variation in the <italic toggle="yes">S</italic>-protein between CoVs limits the breadth of cross protection against multiple emerging CoVs, and is especially true for <italic toggle="yes">S</italic>-protein only vaccines (<xref rid="B252" ref-type="bibr">Wang et al., 2018</xref>, <xref rid="B255" ref-type="bibr">2019</xref>).</p><p>Learning from natural infection, MERS-CoV specific CD4+ and CD8+ T cells are detected in PBMCs in MERS-CoV infected survivors (<xref rid="B280" ref-type="bibr">Zhao et al., 2017</xref>). Therefore, a balance of B cell and T cell responses is generally considered the gold standard to prevent and resolve MERS-CoV and SARS-CoV infection. Multiple strategies have been developed to elicit long lasting B and T cell responses for SARS-CoV and MERS-CoV. These include the traditional live attenuated, inactivated, and subunit vaccines, and newer development of nanoparticles, vectorized vaccines, and RNA/DNA vaccines. In this review, we have selected only the vaccine studies that have an <italic toggle="yes">in vivo</italic> challenge model and have summarized the different parameters, including vaccine components, dosage, challenge conditions, animal models and the study outcome in <xref rid="T1" ref-type="table">Table 1</xref>. We will also discuss each type of vaccine strategy and focus on the finished clinical trial targeting SARS-CoV and the 3 ongoing clinical trials targeting MERS-CoV using DNA (<xref rid="B158" ref-type="bibr">Martin et al., 2008</xref>; <xref rid="B172" ref-type="bibr">Modjarrad et al., 2019</xref>) and vectorized vaccines. Other comprehensive reviews on CoV vaccine development can be found elsewhere (<xref rid="B278" ref-type="bibr">Zhang et al., 2014</xref>; <xref rid="B70" ref-type="bibr">Du and Jiang, 2015</xref>; <xref rid="B194" ref-type="bibr">Perlman and Vijay, 2016</xref>; <xref rid="B211" ref-type="bibr">Schindewolf and Menachery, 2019</xref>; <xref rid="B271" ref-type="bibr">Yong et al., 2019</xref>).</p><table-wrap id="T1" position="float" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of SARS-CoV and MERS-CoV vaccines studies</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>SARS-CoV Vaccines</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Antigens</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Vaccine formulations</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Dose, Time of vaccination</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Animal models</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Challenge dose. Virus strains, Time after last vaccination, Route</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Results</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Whole Inactivated Vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV FRA (<italic toggle="yes">b</italic>-propiolactone) + MF59</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g at 0, 2, and 4 weeks, SC</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 SARS-CoV Urbani, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in Lung and Nasal Turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B225" ref-type="bibr">Stadler et al., 2005</xref> EID</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV Tor2 (<italic toggle="yes">b</italic>-propiolactone) + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g at 0 and 4 weeks, SC</td><td valign="top" align="left" rowspan="1" colspan="1">6 week old 129S6/SvEv</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B213" ref-type="bibr">See et al., 2006</xref> JGV</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Double Inactive</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV (Utah) formaldehyde and UV inactivation + Al(OH)3</td><td valign="top" align="left" rowspan="1" colspan="1">0.08 &#8211; 0.2 &#956;g at week 0 and 2, SC</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 8 weeks CD1 mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50 SARS-CoV Utah at week 3 or 11, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung and trachea</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B224" ref-type="bibr">Spruth et al., 2006</xref> Vaccines</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV Tor2 (<italic toggle="yes">b</italic>-propiolactone) + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g at 0 and 4 weeks, SC</td><td valign="top" align="left" rowspan="1" colspan="1">8 &#8211; 10 month old ferret</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Weak protection, slight reduction of viral titer in lung, BAL and nasal wash, slight improvement in lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B212" ref-type="bibr">See et al., 2008</xref> JGV</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV Urbina (<italic toggle="yes">b</italic>-propiolactone) + AS01B and AS03A</td><td valign="top" align="left" rowspan="1" colspan="1">0.15 &#8211; 1.5 &#956;g at week 0 and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50 SARS-CoV Urbani at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B208" ref-type="bibr">Roberts et al., 2010</xref> Viral Immunology</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV Urbina (<italic toggle="yes">b</italic>-propiolactone) + AS01B and AS03A</td><td valign="top" align="left" rowspan="1" colspan="1">2.0 &#956;g at week 0 and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 8 week old Golden syrian hamsters</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 SARS-CoV Urbani at week 4 or 18, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Partial protection, reduce viral titer in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B208" ref-type="bibr">Roberts et al., 2010</xref> Viral Immunology</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Double Inactive</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV MA15 formalin and UV inactivated + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">0.2 &#956;g at week 0 and 3&#8211;4 week, footpad</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 8 weeks old BALB/cAnNHsd</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU SARS-CoV MA15, SZ61and GD03 at week 5, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Partial protection, reduce viral titer in lung and good protection from lethal challenge (MA15)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B28" ref-type="bibr">Bolles et al., 2011a</xref> JVI</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Double Inactive</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV MA15 formalin and UV inactivated + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">0.2 &#956;g at week 0 and 3&#8211;4 week, footpad</td><td valign="top" align="left" rowspan="1" colspan="1">12 &#8211; 14 months old BALB/cAnNHsd</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU SARS-CoV MA15, SZ61and GD03 at week 5, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Weak protection, small drop in viral titer in lung, weak protection from leathal challenge (MA15)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B28" ref-type="bibr">Bolles et al., 2011a</xref> JVI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAV</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-&#916;E (Urbani)</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-&#916;E (Urbani)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 at 0 week, IN</td><td valign="top" align="left" rowspan="1" colspan="1">7 week old Golden syrian hamsters</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 SARS-CoV Urbani and GD03 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B127" ref-type="bibr">Lamirande et al., 2008</xref> JVI</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SARS-C0V ExoN (MA15)</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-ExoN (MA15)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>2.5</sup> or 10<sup>4</sup> PFU at week</td><td valign="top" align="left" rowspan="1" colspan="1">12 months old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>2.5</sup> TCID50 SARS-CoV MA15 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B87" ref-type="bibr">Graham et al., 2012</xref> Nat Med</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV &#916;NSP16</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV &#916;2&#8242;-<italic toggle="yes">O</italic>-Methyltransferase</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>2</sup> PFU at week 0, IN</td><td valign="top" align="left" rowspan="1" colspan="1">10 weeks old BALB/c and C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU SARS-CoV MA15 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no viral titer performed</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B165" ref-type="bibr">Menachery et al., 2014</xref> JVI</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV &#916;NSP16/ExoN</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV &#916;2&#8242;-<italic toggle="yes">O</italic>-Methyltransferase and ExoN mutation</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>2</sup> PFU at week 0, IN</td><td valign="top" align="left" rowspan="1" colspan="1">12 months old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU SARS-CoV MA15 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B163" ref-type="bibr">Menachery et al., 2018</xref> JVI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit</td><td valign="top" align="left" rowspan="1" colspan="1">subunit nS Sf9</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S (14-762) Urbani + QS21</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g at week 0, 4, and 8, SC</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50 SARS-CoV (Urbani) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B26" ref-type="bibr">Bisht et al., 2005</xref> Virology</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ectodomain Sf9</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S ectodomain (Urbani) + Protollin</td><td valign="top" align="left" rowspan="1" colspan="1">10 or 30 &#956;g at week 0, 2 and 5, IN</td><td valign="top" align="left" rowspan="1" colspan="1">&#8764; 1 year old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">5x10<sup>4</sup> TCID50 SARS-CoV Urbani at week 1, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B102" ref-type="bibr">Hu et al., 2007</xref> Vaccines</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Subunit RBD219 CHO</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV RBD (318-536)Tor2 + Freund</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g at week 0 and 10 &#956;g at week 3 and 6, SC</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">5x10<sup>5</sup> TCID50 SARS-CoV GZ50 at 10 day, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B72" ref-type="bibr">Du et al., 2010</xref> viral immunology</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit Trimer</td><td valign="top" align="left" rowspan="1" colspan="1">Spike trimer</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV RBD Spike Trimer Urbani + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g at week 0, 3, and 6, SC</td><td valign="top" align="left" rowspan="1" colspan="1">5 weeks old Golden syrian hamsters</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 SARS-CoV Urbani at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung and reduce pneumonitis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B112" ref-type="bibr">Kam et al., 2007</xref> Vaccines</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VLP</td><td valign="top" align="left" rowspan="1" colspan="1">MHV-S VLP</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S in MHV + Alum</td><td valign="top" align="left" rowspan="1" colspan="1">2 &#956;g at 0 and 4 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 8 week old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50 SARS-CoV at week 8, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protect, no virus detected in Lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B147" ref-type="bibr">Lokugamage et al., 2008</xref> Vaccine</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Flu M1-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S Urbani in influenza M1 + Al(OH)3</td><td valign="top" align="left" rowspan="1" colspan="1">0.8 or 4 &#956;g at week 0 and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 8 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">2xLD50 mouse adapted SARS-CoV V2163 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B145" ref-type="bibr">Liu et al., 2011</xref> Vaccines</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid <italic toggle="yes">S</italic>-Ectodomain</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid expressing SARS-CoV S &#916;CD or ectodomain (Urbani)</td><td valign="top" align="left" rowspan="1" colspan="1">25 &#956;g at week 0, 3, and 6, IM</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 8 week old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 SARS-CoV Urbani, at Day 30, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B268" ref-type="bibr">Yang et al., 2004</xref> Nature</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vector</td><td valign="top" align="left" rowspan="1" colspan="1">BHPIV3 SARS-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S or SME Urbani in parainfluenza virus type 3 vector (BHPIV3)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50 at 0 week, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Golden syrian hamsters</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 SARS-CoV Urbani at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B31" ref-type="bibr">Buchholz et al., 2004</xref> PNAS</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">BHPIV3 SARS-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S Urbani in parainfluenza virus type 3 vector (BHPIV3)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50 each at 0 week, IN and IT</td><td valign="top" align="left" rowspan="1" colspan="1">African green monkeys</td><td valign="top" align="left" rowspan="1" colspan="1">&#8220;A large dose of SARS-CoV&#8221; at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B32" ref-type="bibr">Bukreyev et al., 2004</xref> Lancet</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MVA-SARS-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S Urbani in MVA</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>7</sup> at 0 and 4 week, IN</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 SARS-CoV Urbani, at week 8, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B25" ref-type="bibr">Bisht et al., 2004</xref> PNAS</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MVA-SARS-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S Urbani in MVA</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>7</sup> at 0 and 4 week, IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 SARS-CoV Urbani, at week 8, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B25" ref-type="bibr">Bisht et al., 2004</xref> PNAS</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MVA-SARS-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S and N Tor2 in MVA</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>8</sup> pfu at 0 and 5 &#215; 10<sup>7</sup> at 2 week, IP and SC</td><td valign="top" align="left" rowspan="1" colspan="1">Ferret</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">No protection according to viral RNA in lung, Ab induction</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B54" ref-type="bibr">Czub et al., 2005</xref> Vaccines</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">VSV-S</td><td valign="top" align="left" rowspan="1" colspan="1">VSV-SARS-S Urbani</td><td valign="top" align="left" rowspan="1" colspan="1">1.4 &#215; 10<sup>4</sup> pfu at week 0, IN</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 SARS-CoV Urbani at month 1 and 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B114" ref-type="bibr">Kapadia et al., 2005</xref> Virology</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">hAd5 (N+S)</td><td valign="top" align="left" rowspan="1" colspan="1">Human Adenovirus 5 with S + Ad5 N gene</td><td valign="top" align="left" rowspan="1" colspan="1">3 &#215; 10<sup>8</sup> pfu each at 0 and 4 weeks, IM</td><td valign="top" align="left" rowspan="1" colspan="1">6 week old 129S6/SvEv</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">No protection despite strong IgG1, IgG2a Ab induction and high IFN-g secretion</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B213" ref-type="bibr">See et al., 2006</xref> JGV</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">hAd5 (N+S)</td><td valign="top" align="left" rowspan="1" colspan="1">Human Adenovirus 5 with S + Ad5 N gene</td><td valign="top" align="left" rowspan="1" colspan="1">3 &#215; 10<sup>8</sup> pfu each at 0 and 4 weeks, IN</td><td valign="top" align="left" rowspan="1" colspan="1">6 week old 129S6/SvEv</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Partial protection, Induction of IgA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B213" ref-type="bibr">See et al., 2006</xref> JGV</td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>MERS-CoV Vaccines</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Antigens</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Vaccine formulations</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Dose, Time of vaccination</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Animal models</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Challenge dose. Virus strains, Time after last vaccination, Route</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Results</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">VEEV-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV GD03 S in VEEV</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> IU at 0 week, boost 3 &#8211; 5 weeks, footpad</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 7 weeks old</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> pfu SARS-CoV GD03 and Urbani at week 7 &#8211; 8 and week 54, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B62" ref-type="bibr">Deming et al., 2006</xref> PlOS Med</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">VEEV-S</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV GD03 S in VEEV</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> IU at 0 week, boost 3 - 5 week, footpad</td><td valign="top" align="left" rowspan="1" colspan="1">&gt; 26 week old</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> pfu SARS-CoV GD03 and Urbani at week 7 -8 and week 54, IN</td><td valign="top" align="left" rowspan="1" colspan="1">No protection</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B62" ref-type="bibr">Deming et al., 2006</xref> PlOS Med</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">hAd5-S + AdC7-S</td><td valign="top" align="left" rowspan="1" colspan="1">Human Adenovirus 5 with S + Chimpanzee AdC7 with S Tor2</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#215; 10<sup>11</sup> VP/kg at 0 and 1 month, IM</td><td valign="top" align="left" rowspan="1" colspan="1">18 &#8211; 20 weeks old ferret</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at not specify, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinates</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B125" ref-type="bibr">Kobinger et al., 2007</xref> Vaccines</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">hAd5 (N+S)</td><td valign="top" align="left" rowspan="1" colspan="1">Human Adenovirus 5 with S + Ad5 N gene</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>9</sup> pfu each at 0 and 4 weeks, IM</td><td valign="top" align="left" rowspan="1" colspan="1">8 - 10 month old ferret</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Inconclusive, control hAd5 shows non-specific protection</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B212" ref-type="bibr">See et al., 2008</xref> JGV</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">hAd5 (N+S)</td><td valign="top" align="left" rowspan="1" colspan="1">Human Adenovirus 5 with S + Ad5 N gene</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>9</sup> pfu each at 0 and 4 weeks, IN</td><td valign="top" align="left" rowspan="1" colspan="1">8 &#8211; 10 months old ferret</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> pfu SARS-CoV Tor2 at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Inconclusive, control hAd5 shows non-specific protection</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B212" ref-type="bibr">See et al., 2008</xref> JGV</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Whole Inactivaed Vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV (&#947;-ray) + Alum or MF59</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50 at week 0 and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">hCD26/DPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 (100xLD50) MERS-CoV at week 3, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection from virus replication, no virus detected in lung, increase lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B7" ref-type="bibr">Agrawal et al., 2016</xref> Human vaccine and immuno therapy</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV EMC/2012 (formaldehyde) + Alum and CpG</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#956;g at week 0, 4 and 8, IM</td><td valign="top" align="left" rowspan="1" colspan="1">14 &#8211; 16 week old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU MERS-CoV (EMC/2012) at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B64" ref-type="bibr">Deng et al., 2018</xref> Emerging Microbes and infection</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAV</td><td valign="top" align="left" rowspan="1" colspan="1">MERSS-CoV &#916;NSP16</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV &#916;2&#8242;-<italic toggle="yes">O</italic>-Methyltransferase EMC MA1</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> PFU at week 0, IN</td><td valign="top" align="left" rowspan="1" colspan="1">10 - 20 week old C57BL/6 288-330+/+</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> PFU MERS-CoV EMC MA1 at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, reduce viral titer in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B162" ref-type="bibr">Menachery et al., 2017</xref> msphere</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV RBD S367-606 (EMC/2012) + alum</td><td valign="top" align="left" rowspan="1" colspan="1">200 &#956;g at week 0 and 100 &#956;g at week 8 and 25, IM</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus Macaque</td><td valign="top" align="left" rowspan="1" colspan="1">6.5x10<sup>7</sup> TCID50 MERS-CoV (EMC/2012) at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Partial protection, reduce viral titer in lung and trachea</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B129" ref-type="bibr">Lan et al., 2015</xref> EBioMedicine</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NTD</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV NTD S18-353 (EMC/2012) + alum and CpG</td><td valign="top" align="left" rowspan="1" colspan="1">5 or 1 &#956;g at week 0, 4 and 8, IM</td><td valign="top" align="left" rowspan="1" colspan="1">16 &#8211; 18 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU MERS-CoV (EMC/2012) at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Partial protection, reduce lung and trachea pathologies, no viral titer information</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B108" ref-type="bibr">Jiaming et al., 2017</xref> Vaccines</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">S ectodomain</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV EMC/2012 S ectodomain + Alum and CpG</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#956;g at week 0, 4 and 8, IM</td><td valign="top" align="left" rowspan="1" colspan="1">14 &#8211; 16 week old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU MERS-CoV (EMC/2012) at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduction in lung viral titer</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B64" ref-type="bibr">Deng et al., 2018</xref> Emerging Microbes and infection</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RBD-Fc</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV RBD S377-588 Fc (EMC/2012) + MF59</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g at week 0, 3, and 6, SC</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU MERS-CoV (EMC/2012) at week 2, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B277" ref-type="bibr">Zhang et al., 2016</xref> Cellular and molecular immunology</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RBD-Fc</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV RBD S377-588 Fc (EMC/2012) + Addavax</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g at week 0 and 4, IM</td><td valign="top" align="left" rowspan="1" colspan="1">hCD26/DPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 (100xLD50) MERS-CoV (EMC/2012) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B181" ref-type="bibr">Nyon et al., 2018</xref> Vaccines</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">S1</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV ENgland1 S1 + Advax HCXL or Sigma oil-in-water emulsion</td><td valign="top" align="left" rowspan="1" colspan="1">400 &#956;g at week 0, 4 and 15, IM</td><td valign="top" align="left" rowspan="1" colspan="1">dromedary camel</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>7</sup> TCID50 MERS-CoV (EMC/2012) at &#8764;week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung and nasal turbinate</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Adney et al., 2019</xref> Virus</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">S1</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV ENgland1 S1 + Advax HCXL or Sigma oil-in-water emulsion</td><td valign="top" align="left" rowspan="1" colspan="1">400 &#956;g at week 0, 4, and 15, IM</td><td valign="top" align="left" rowspan="1" colspan="1">Alpaca</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>7</sup> TCID50 MERS-CoV (EMC/2012) at &#8764;week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung, nasal turbinate and nasal swabs</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Adney et al., 2019</xref> Virus</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subunit Trimer</td><td valign="top" align="left" rowspan="1" colspan="1">RBD Trimer</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV RBD-Fd (Trimer) + alum</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g at week 0 and 4, IM</td><td valign="top" align="left" rowspan="1" colspan="1">hCD26/DPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 MERS-CoV (EMC/2012) at week 12, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no viral titer performed</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B231" ref-type="bibr">Tai et al., 2016</xref> Virology</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VLP</td><td valign="top" align="left" rowspan="1" colspan="1">S nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV Jordan S nanoparticle + Matrix M1</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g at week 0 and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">15 &#8211; 17 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">2.5 &#215; 10<sup>3</sup> PFU MERS-CoV (Jordan) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection from chalenge, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B48" ref-type="bibr">Coleman et al., 2017</xref> Vaccines</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">BNSP333-S</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S1 Jordan fused with rabies virus G protein VLP</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g at week 0, 1, and 3, IM</td><td valign="top" align="left" rowspan="1" colspan="1">15 &#8211; 17 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">2.5 &#215; 10<sup>3</sup> PFU MERS-CoV (Jordan) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, no virus detected in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B260" ref-type="bibr">Wirblich et al., 2017</xref> JVI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid S-protein</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid expressing MERS-CoV S1 (Al-Hasa_1_2013)</td><td valign="top" align="left" rowspan="1" colspan="1">0.5 or 2 mg at week 0, 3 and 6, IM</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus macaques</td><td valign="top" align="left" rowspan="1" colspan="1">7 &#215; 10<sup>6</sup> TCID50 MERS-CoV (EMC/2012) at week 5, IT, IN, oral and ocular</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung, reduce clinical pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B177" ref-type="bibr">Muthumani et al., 2015</xref> STM</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Plasmid S1</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid expressing MERS-CoV S1 (Al-Hasa_15_2013)</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g at week 0, 3 and 6, IM</td><td valign="top" align="left" rowspan="1" colspan="1">14 - 16 week old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU MERS-CoV (EMC/2012) at Day 18, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B43" ref-type="bibr">Chi et al., 2017</xref> Vaccines</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vector</td><td valign="top" align="left" rowspan="1" colspan="1">MVvca2 S or soluble S</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant measles virus with MERS-CoV (EMC/2012) S or soluble S</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50 at week 0 and 4, IP</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#8211; 12 week old IFNAR&#8722;/&#8722; CD46Ge transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">7 &#215; 10<sup>4</sup> TCID50 MERS-CoV (EMC/2012) at week 6, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral titer in lung, reduce lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B157" ref-type="bibr">Malczyk et al., 2015</xref> JVI</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">ChAdOx1 MERS</td><td valign="top" align="left" rowspan="1" colspan="1">ChAdOx1 with MERS-CoV <italic toggle="yes">S</italic>-protein (EMC/2012)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>8</sup> IU at week 0, IN or IM</td><td valign="top" align="left" rowspan="1" colspan="1">hCD26/DPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50 MERS-CoV (EMC/2012) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung, reduce lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B175" ref-type="bibr">Munster et al., 2017</xref> npj</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MVA-MERS-S</td><td valign="top" align="left" rowspan="1" colspan="1">MVA with MERS-CoV <italic toggle="yes">S</italic>-protein</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup>, 10<sup>7</sup>, or 10<sup>8</sup> PFU at week 0, IM or SC</td><td valign="top" align="left" rowspan="1" colspan="1">14 &#8211; 16 week old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">7 &#215; 10<sup>4</sup> TCID50 MERS-CoV (EMC/2012) at week 6, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Protection, reduce viral RNA genome in lung, reduce lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B246" ref-type="bibr">Volz et al., 2015</xref> JVI</td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">rAd5-S1/F/CD40L</td><td valign="top" align="left" rowspan="1" colspan="1">hAd5 with MERS-CoV S1 trimer fused with CD40L</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>9</sup> PFU at week 0 and 4, IM</td><td valign="top" align="left" rowspan="1" colspan="1">hCD26/DPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> TCID50 (100xLD50) MERS-CoV (EMC/2012) at week 4, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Complete survival from lethal challenge, no virus detected in lung, reduce lung pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B98" ref-type="bibr">Hashem et al., 2019</xref> JID</td></tr></tbody></table><table-wrap-foot><attrib><italic toggle="yes">Selection criteria: Only animal studies with a challenge model are included. LAV, live attenuated vaccine; VLP, virus like particle; RBD, receptor binding domain; IM, intramuscular; IN, intranasal; SC, subcutaneous; IP, intraperitoneal.</italic></attrib></table-wrap-foot></table-wrap></sec><sec id="S2.SS2"><title>Current Vaccine Strategies</title><p>Inactivated vaccines are the quickest option for vaccine development in an outbreak situation. Multiple chemical and physical methods have been applied singly or in combination to inactivate CoVs, including &#946;-propiolactone, formalin, formaldehyde and UV. While multiple studies have shown the efficacy of inactivated vaccines in hamster, ferret and multiple mouse challenge models (<xref rid="B225" ref-type="bibr">Stadler et al., 2005</xref>; <xref rid="B213" ref-type="bibr">See et al., 2006</xref>, <xref rid="B212" ref-type="bibr">2008</xref>; <xref rid="B224" ref-type="bibr">Spruth et al., 2006</xref>; <xref rid="B208" ref-type="bibr">Roberts et al., 2010</xref>), one study suggested a potential vaccine enhanced pathologies (<xref rid="B28" ref-type="bibr">Bolles et al., 2011a</xref>). In this study, double inactivation (DIV) of SARS-CoV using formalin and UV+alum elicits a Th2 skewed response and is only partially protective to young mice (6&#8211;8 weeks-old) and not protective to experimentally aged mice (12&#8211;14 weeks-old) (<xref rid="B28" ref-type="bibr">Bolles et al., 2011a</xref>). Furthermore, upon challenge, DIV vaccinated mice show increased infiltration of eosinophils, neutrophils and other inflammatory cell populations in the lung, likely due to the N specific immune response (<xref rid="B28" ref-type="bibr">Bolles et al., 2011a</xref>). Further studies have suggested that by replacing alum with TLR agonists such as Poly I:C, Poly U or LPS as adjuvants, the skewed Th2 responses can be alleviated and may reduce the infiltration of eosinophils in the lung (<xref rid="B106" ref-type="bibr">Iwata-Yoshikawa et al., 2014</xref>).</p><p>Gamma-ray inactivated whole MERS-CoV (WIV) with alum or M59 also suffers from the Th2 skewed immune response and pulmonary eosinophilia upon challenge, suggesting a potential risk of using inactive virus for CoV vaccination (<xref rid="B7" ref-type="bibr">Agrawal et al., 2016</xref>). Interestingly, formaldehyde inactivated MERS-CoV co-administered with alum and CpG shows a more balanced Th1/Th2 response and is able to protect mice from a challenge model (Ad5 transduced hDPP4) with reduction in lung viral titer and improved lung pathology. There is no observable vaccine-induced lung pathology or infiltration of eosinophils upon challenge (<xref rid="B64" ref-type="bibr">Deng et al., 2018</xref>). The difference in vaccine outcomes indicates an incomplete understanding of the effect of adjuvants on the inactivated SARS and MERS-CoV vaccines. In respiratory syncytial virus (RSV) vaccines, formalin inactivated vaccines presents the post-fusion form predominately and fail to elicit protective immune responses. Whether the same phenomenon exists in inactivated CoV is still unknown, although it could explain the discrepancy between reports. The inconsistent results from different vaccine models also underscores the host genetic elements affecting vaccine outcome. Nevertheless, inactivated vaccine is still one of the most straightforward methods for vaccine development and has the quickest response time in an outbreak situation.</p><p>Live attenuated viral vaccines are the closest mimic of natural infection and generally elicit strong B and T cell responses (<xref rid="B280" ref-type="bibr">Zhao et al., 2017</xref>). Multiple strategies have been used to genetically attenuate SARS-CoV and MERS-CoV by either deleting or mutating structural, non-structural or accessory proteins. Intranasal immunization of a SARS-CoV lacking E protein (rSARS-CoV-&#916;E) has shown complete protection from pulmonary replication in a Golden Syrian hamster model (<xref rid="B127" ref-type="bibr">Lamirande et al., 2008</xref>). A similar virus has been generated in the MERS backbone, creating a conditional mutant that requires trans expression of E for productive replication (<xref rid="B13" ref-type="bibr">Almaz&#225;n et al., 2013</xref>). Mutations of the DEDD motif of the 3&#8242; to 5&#8242; exonuclease (ExoN-nsp14) &#8220;proof-reading protein&#8221; on a mouse-adapted SARS-CoV attenuated the virus both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. A single intranasal immunization is able to elicit strong nAbs (&gt;6-fold protective titers) and completely protect against lethal challenges in an aged mouse model (12 months-old BALB/c) (<xref rid="B87" ref-type="bibr">Graham et al., 2012</xref>). Mutations in the nsp 16 (NSP16), a 2&#8242;<italic toggle="yes">O</italic>-methyltransferase, in both SARS-CoV and MERS-CoV have also been shown to attenuate the viruses and to protect BALB/c and CRISPR-Cas humanized DPP4-288-330 mice from lethal challenge (<xref rid="B165" ref-type="bibr">Menachery et al., 2014</xref>, <xref rid="B162" ref-type="bibr">2017</xref>, <xref rid="B163" ref-type="bibr">2018</xref>). Moreover, these attenuation strategies can be multiplexed, leading to highly stable live attenuated vaccines with limited capability to undergo recombination and reversion repair (<xref rid="B88" ref-type="bibr">Graham et al., 2018</xref>; <xref rid="B163" ref-type="bibr">Menachery et al., 2018</xref>). Although the live attenuated vaccine is effective in small animal models, there remain safety concerns about potential revertants and recombination with natural CoVs which hinders their usage in the clinical setting. Furthermore, live attenuated vaccines often require greater time for development and safety testing which lessens utility in an outbreak situation.</p><p>Protein-based subunit vaccines are considered the safest format of vaccine. However, the low immunogenicity of subunit vaccines dictates a heavily reliance on adjuvants. Different forms of the <italic toggle="yes">S</italic>-protein, including the S1 RBD, RBD-Fc (RBD with human IgG Fc fusion), and N-terminal domain (NTD), have demonstrated various degrees of nAb responses and protection in multiple animal models including non-human primates (NHP) (<xref rid="B129" ref-type="bibr">Lan et al., 2015</xref>; <xref rid="B277" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="B108" ref-type="bibr">Jiaming et al., 2017</xref>; <xref rid="B251" ref-type="bibr">Wang et al., 2017</xref>; <xref rid="B64" ref-type="bibr">Deng et al., 2018</xref>; <xref rid="B181" ref-type="bibr">Nyon et al., 2018</xref>; <xref rid="B3" ref-type="bibr">Adney et al., 2019</xref>). For instance, the SARS-CoV S1 subunit vaccine produced from sf9 cells and with the adjuvant saponin or protollin are able to reduce lung viral titer in young or aged mice after challenge, respectively (<xref rid="B26" ref-type="bibr">Bisht et al., 2005</xref>; <xref rid="B102" ref-type="bibr">Hu et al., 2007</xref>). An RBD subunit of SARS-CoV produced from Chinese hamster ovarian (CHO) cells with Freund&#8217;s adjuvant is able to protect young BALB/c mice from infection (<xref rid="B72" ref-type="bibr">Du et al., 2010</xref>). MERS-CoV-S1 with adjuvants MF59 or Advax HCXL is able to protect alpacas and dromedary camels against MERS-CoV challenge (<xref rid="B3" ref-type="bibr">Adney et al., 2019</xref>). Adjuvant selection can affect the vaccine outcome, and combinations of adjuvants can have synergistic effects on the strength of the response. For instance, rRBD with adjuvants alum and CpG ODN together elicits a stronger humoral and cellular T cell response (<xref rid="B128" ref-type="bibr">Lan et al., 2014</xref>). Additionally, rNTD with alum is able to reduce lung pathology in a non-lethal MERS-CoV challenge (<xref rid="B108" ref-type="bibr">Jiaming et al., 2017</xref>). Instead of adjuvants alone, immune enhancers such as an Fc fragment, which increases the protein half-life when fused with the RBD, can also elicit a stronger IgG nAb and cellular immune response in multiple experimental animals (<xref rid="B71" ref-type="bibr">Du et al., 2013</xref>; <xref rid="B154" ref-type="bibr">Ma et al., 2014b</xref>; <xref rid="B234" ref-type="bibr">Tang et al., 2015</xref>; <xref rid="B181" ref-type="bibr">Nyon et al., 2018</xref>). RBD-Fc fusion subunit vaccine is able to protect a lethal challenge of MERS-CoV in adenovirus transduced hCD26/DPP4 mice (<xref rid="B277" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="B251" ref-type="bibr">Wang et al., 2017</xref>). While a large amount of work concerning the subunit vaccines has been done in conjunction with different adjuvants, the effect of each adjuvant is not well understood and multi-adjuvant systems (combinatorial admixes) have not been rigorously tested. A more systematic method of studying the effect of different adjuvants on CoV vaccines will be valuable for vaccine development, perhaps using genetic reference populations that more accurately phenocopy human genetic variation (<xref rid="B133" ref-type="bibr">Leist and Baric, 2018</xref>).</p><p>Trimeric forms of the <italic toggle="yes">S</italic>-protein and RBD have been developed using the T4 trimerization domain to mimic the native conformation of the spike RBD (<xref rid="B112" ref-type="bibr">Kam et al., 2007</xref>; <xref rid="B231" ref-type="bibr">Tai et al., 2016</xref>). The trimeric RBD antigens are able to elicit a robust nAb response and protect 80% of hDPP4 transgenic mice from lethal MERS-CoV challenge, although most animals still experienced slight weight loss (<xref rid="B231" ref-type="bibr">Tai et al., 2016</xref>). Alternatively, the MERS-CoV <italic toggle="yes">S</italic>-protein has been structurally designed to remain in perfusion state by mutating V1060 and L1061 at the tip of the central helix to proline (S-2P) (<xref rid="B122" ref-type="bibr">Kirchdoerfer et al., 2016</xref>; <xref rid="B186" ref-type="bibr">Pallesen et al., 2017</xref>). The MERS S-2P protein retains the receptor binding properties of the wild-type S and elicits nAbs against at least 3 different S domains, including RBD, NTD, and S2. Intramuscular injection of the MERS S-2P elicits nAb responses in mice comparable to the monomeric S1 and trimeric <italic toggle="yes">S</italic>-protein antigens. (<xref rid="B186" ref-type="bibr">Pallesen et al., 2017</xref>).</p><p>Similar to subunit vaccines are the viral like particle (VLP) and nanoparticle vaccines. VLP and nanoparticles provide multivalent binding similar to actual viruses without the potential safety concerns. In SARS-CoV, multiple systems were used to generate <italic toggle="yes">S</italic>-protein VLPs, including the mouse hepatitis virus (MHV) and influenza matrix 1 (M1). In the chimeric MHV system, the SARS-CoV protein is co-expressed with the MHV E, M and N proteins to produce MHV-S VLP. Mice vaccinated with the MHV-S VLP and alum have inhibited viral replication in lung after a homologous strain challenge (<xref rid="B147" ref-type="bibr">Lokugamage et al., 2008</xref>). Instead of using MHV structural proteins, the influenza system express the SARS-CoV <italic toggle="yes">S</italic>-protein with influenza virus M1 proteins in Sf9 cells to create the M1-S VLP. Immunization of M1-S VLP with aluminum hydroxide can protect mice from a lethal challenge of SARS-CoV (<xref rid="B145" ref-type="bibr">Liu et al., 2011</xref>). In MERS-CoV, expression of S, E, and M proteins using the baculovirus system produces VLPs that are morphologically similar to the actual virus (<xref rid="B47" ref-type="bibr">Coleman et al., 2014</xref>; <xref rid="B250" ref-type="bibr">Wang et al., 2017b</xref>). Other methods such as CPV-based (<xref rid="B249" ref-type="bibr">Wang et al., 2017a</xref>), rabies virus (MV)-based (<xref rid="B260" ref-type="bibr">Wirblich et al., 2017</xref>), ferritin-based (<xref rid="B214" ref-type="bibr">Seong, 2018</xref>), and <italic toggle="yes">S</italic>-protein aggregates (<xref rid="B47" ref-type="bibr">Coleman et al., 2014</xref>) are all able to elicit immune responses and reduce viral replication in a mouse model when co-administered with Matrix M1 adjuvant (<xref rid="B48" ref-type="bibr">Coleman et al., 2017</xref>). Although all show different degree of immune response in animal, only one study showed a reduction of viral titer <italic toggle="yes">in vivo</italic> via an adenovirus transduced hCD26/DPP4 mouse model (<xref rid="B48" ref-type="bibr">Coleman et al., 2017</xref>).</p></sec><sec id="S2.SS3"><title>Clinical Trials for SARS- and MERS-CoV Vaccines</title><p>A finished phase 1 clinical trial for a SARS-CoV vaccine is a DNA vaccine that encodes the ectodomain of the SARS-CoV <italic toggle="yes">S</italic>-protein (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00099463">NCT00099463</ext-link>). DNA vaccines rely on a continuous expression of antigen from a DNA plasmid that is injected intramuscularly and electroporated (<xref rid="B177" ref-type="bibr">Muthumani et al., 2015</xref>; <xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>; <xref rid="B43" ref-type="bibr">Chi et al., 2017</xref>). In pre-clinical studies, 3 doses of an intramuscular plasmid injection was able to reduce viral titer in both lung and nasal turbinate in a BALB/c challenge model (<xref rid="B268" ref-type="bibr">Yang et al., 2004</xref>). The phase 1 trial showed favorable results; after 3 doses of DNA vaccine, all subjects showed CD4+ T cell responses, while 80% of subjects had nAbs and 20% of subjects showed CD8+ T cell responses. However, there has been no follow-up in the vaccine development, likely due to the end of the SARS-CoV outbreak (<xref rid="B158" ref-type="bibr">Martin et al., 2008</xref>). One MERS-CoV vaccine that is currently undergoing clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03721718">NCT03721718</ext-link>) is a DNA-based vaccine (<xref rid="B172" ref-type="bibr">Modjarrad et al., 2019</xref>). GLS-5300 is a DNA vaccine based on a consensus full-length <italic toggle="yes">S</italic>-protein from MERS-CoV under the control of a CMV promoter. In preclinical studies, the vaccine was electroporated into mice, camel and rhesus monkeys three times within 1 month. The vaccine elicited B cell responses in all animals at 1 month post vaccination, and extracted IgG was able to neutralize multiple strains of MERS-CoV including England/2/2013, and Al-Hasa/1/2013 and, surprisingly, a group 1b CoV NL63 and a group 2a CoV HKU1 using the pseudotype neutralization assay (<xref rid="B177" ref-type="bibr">Muthumani et al., 2015</xref>). T cell responses were assessed in mice and monkeys, with both demonstrating T cell responses as indicated by the presence of IFN-&#947;, TNF&#945; and IL2-secreting CD4+ and CD8+ T cells after peptide stimulation. Rhesus monkeys were also protected from challenge of the vaccine strain with lower viral titers and lung pathology as assessed by radiography and pathology studies (<xref rid="B177" ref-type="bibr">Muthumani et al., 2015</xref>). Currently, GLS-5300 has completed Phase I clinical trials (safety). Three doses (0.67, 2, and 6 mg) of GLS-5300 were electroporated intramuscularly at weeks 0, 4, and 12. Ninety-four percent of subjects were seroconverted and nAbs were detected in 50% of the individuals. Seventy-six percent of subjects developed T-cell responses against peptides derived from MERS-CoV <italic toggle="yes">S</italic>-proteins (<xref rid="B172" ref-type="bibr">Modjarrad et al., 2019</xref>). Other than a full <italic toggle="yes">S</italic>-protein DNA vaccine, different designs also show promising results in preclinical mouse models. Notably, a DNA vaccine composed of only the S1 domain showed efficacy when paired with different adjuvants (<xref rid="B43" ref-type="bibr">Chi et al., 2017</xref>). Hybrid strategies using a DNA vaccine paired with a protein booster also showed promising results in eliciting more balanced Th1 and Th2 responses (<xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>; <xref rid="B10" ref-type="bibr">Al-Amri et al., 2017</xref>).</p></sec><sec id="S2.SS4"><title>Vector-Based Vaccines</title><p>Two out of the three clinical trials for MERS vaccines are vectorized vaccines. Viral vector-based vaccines have multiple advantages over the generic protein or DNA-based subunit vaccines. Firstly, as viral vectors utilize a defined viral entry mechanism, they are more efficient at delivering DNA into cells. Second, the vector itself can serve as an adjuvant which in turn elicits both B- and T-cell responses (<xref rid="B242" ref-type="bibr">Ura et al., 2014</xref>). Finally, a wide variety of vector systems including measles viruses (<xref rid="B157" ref-type="bibr">Malczyk et al., 2015</xref>; <xref rid="B27" ref-type="bibr">Bodmer et al., 2018</xref>), Venezuelan equine encephalitis virus (VEEV) replicon system (<xref rid="B62" ref-type="bibr">Deming et al., 2006</xref>; <xref rid="B4" ref-type="bibr">Agnihothram et al., 2014</xref>; <xref rid="B283" ref-type="bibr">Zhao et al., 2016</xref>), adeno-associated virus (AAV) (<xref rid="B73" ref-type="bibr">Du et al., 2008</xref>), parainfluenza type 3 (BHPIV3) (<xref rid="B31" ref-type="bibr">Buchholz et al., 2004</xref>; <xref rid="B32" ref-type="bibr">Bukreyev et al., 2004</xref>), human and chimpanzee adenovirus (hAd5 and ChAdOx1) (<xref rid="B213" ref-type="bibr">See et al., 2006</xref>, <xref rid="B212" ref-type="bibr">2008</xref>; <xref rid="B125" ref-type="bibr">Kobinger et al., 2007</xref>; <xref rid="B120" ref-type="bibr">Kim et al., 2014</xref>; <xref rid="B91" ref-type="bibr">Guo et al., 2015</xref>; <xref rid="B98" ref-type="bibr">Hashem et al., 2019</xref>) and modified vaccinia virus Ankara (MVA) (<xref rid="B25" ref-type="bibr">Bisht et al., 2004</xref>; <xref rid="B54" ref-type="bibr">Czub et al., 2005</xref>; <xref rid="B114" ref-type="bibr">Kapadia et al., 2005</xref>; <xref rid="B93" ref-type="bibr">Haagmans et al., 2016</xref>) have been previously established for use as vaccine platforms for multiple infectious diseases. Herein, we will focus on the three systems that have been or are currently under clinical trial; all others are summarized in <xref rid="T1" ref-type="table">Table 1</xref>.</p><p>Replication-defective adenovirus vectors are one of the most effective choices to deliver vaccine antigens. Human adenovirus 5 (hAd5) and enteric adenovirus type 41 (Ad41) have both been used to deliver MERS-CoV S or S1 proteins. Intramuscular inoculation of the vaccine elicits both B-cell (nAb titer) and T-cell (IFN-&#947; secreting splenocytes and pulmonary lymphocytes) responses (<xref rid="B91" ref-type="bibr">Guo et al., 2015</xref>). However, pre-existing nAbs against hAd5 and 41 in the human population have limited their usage to dromedary camels instead of humans (<xref rid="B44" ref-type="bibr">Chirmule et al., 1999</xref>). The pre-existing nAb problem against hAd5 can be circumvented by using a chimpanzee adenovirus. One such platform is ChAdOx1, wherein the adenovirus E1 gene is replaced by a MERS-CoV <italic toggle="yes">S</italic>-protein with an N-terminal secretion peptide from human plasminogen activator (tPA) driven by a CMV promoter. Intramuscular inoculation of the vector successfully elicits nAbs against <italic toggle="yes">S</italic>-protein as quickly as 14 days post infection. Splenic CD8+ T-cells secreting IFN-&#947;, TNF-&#945; and IL-17 are also present at 28 days post infection (<xref rid="B12" ref-type="bibr">Alharbi et al., 2017</xref>). A single intranasal or intramuscular inoculation of ChAdOx1-MERS is able to protect a human DPP4 transgenic mouse from lethal challenge by MERS-CoV, and the vaccine (<xref rid="B175" ref-type="bibr">Munster et al., 2017</xref>) is currently under phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03399578">NCT03399578</ext-link>). CHAdOx1 has also shown effective protection for Rift Valley Fever Virus in dromedary camels (<xref rid="B257" ref-type="bibr">Warimwe et al., 2016</xref>).</p><p>The modified vaccinia virus Ankara (MVA) vector is another effective platform for MERS-CoV vaccine development. <italic toggle="yes">S</italic>-protein is inserted into the MAV genome at deletion site III driven by the viral P11 promoter. After a single intramuscular injection, BALB/c mice produce nAbs against both the RBD and S2, as tested <italic toggle="yes">in vitro</italic> (<xref rid="B223" ref-type="bibr">Song et al., 2013</xref>). A follow-up study identified IFN-&#947; secreting splenocytes after peptide S291 stimulation at 56 days post infection, suggesting the vaccine is able to elicit memory CD8+ T cell responses. The vaccine is also able to protect a hDDP4-transduced BALB/c mouse model. RNA genomes in the lungs and lung pathology are drastically reduced compared to mock vaccination (<xref rid="B246" ref-type="bibr">Volz et al., 2015</xref>). The MAV based MERS-CoV vaccine has also been tested on dromedary camels and elicits induction of nAbs in sera and nasal swabs. Vaccinated camels also show reduced RNA genomes and gross pathology. The Phase I clinical trial has just been completed and the results are pending (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03615911">NCT03615911</ext-link>).</p></sec></sec><sec id="S3"><title>Antivirals</title><sec id="S3.SS1"><title>The Challenge for Treatment Windows</title><p>The average incubation period for SARS-CoV and MERS-CoV is around 5 days (<xref rid="B288" ref-type="bibr">Zumla et al., 2015</xref>; <xref rid="B61" ref-type="bibr">de Wit et al., 2016</xref>) and the main site of viral replication is the lower respiratory tract (<xref rid="B49" ref-type="bibr">Corman et al., 2015</xref>; <xref rid="B195" ref-type="bibr">Petrovsky, 2016</xref>). At 7&#8211;10 days after symptomatic onset, viral RNA titer peaks in the upper respiratory tract (<xref rid="B69" ref-type="bibr">Drosten et al., 2004</xref>; <xref rid="B49" ref-type="bibr">Corman et al., 2015</xref>). For terminal cases, disease lasts for an average of 12 days post symptomatic onset for MERS-CoV and 24 days for SARS-CoV (<xref rid="B288" ref-type="bibr">Zumla et al., 2015</xref>). Interestingly, severe symptoms begin as the viral titer is decreasing, suggesting that severe CoV pathogenesis is due to immune complications and the inability to resolve inflammation (<xref rid="B191" ref-type="bibr">Peiris et al., 2003a</xref>; <xref rid="B256" ref-type="bibr">Wang et al., 2004</xref>). SARS-CoV upregulates pro-inflammatory cytokine production in the lung, including IL1, IL6, IL8, IL10, CXCL10 and TNF-&#945; production (<xref rid="B24" ref-type="bibr">Binnie et al., 2014</xref>). Compared to SARS-CoV infected patients with mild diseases, patients with ARDS fail to induce interferon (IFN) expression and the subsequent IFN-stimulated genes (ISGs) that are indicative of adaptive immune responses (<xref rid="B34" ref-type="bibr">Cameron et al., 2007</xref>; <xref rid="B24" ref-type="bibr">Binnie et al., 2014</xref>). The inability to switch from an innate immune response to the adaptive immune response may lead to uncontrollable inflammation and severe end stage lung disease. Given the rapid progression of symptoms to terminal illness, there is only approximately a 1 week treatment window after the onset of symptoms for antiviral and medical intervention (<xref rid="B259" ref-type="bibr">Widagdo et al., 2017</xref>). This treatment window could further compromised by delays in virus diagnosis, causing a challenge for timely medical intervention administration when the virus titers and pathological symptom are relatively mild (<xref rid="B49" ref-type="bibr">Corman et al., 2015</xref>; <xref rid="B8" ref-type="bibr">Ahmed, 2019</xref>). Unlike humans, experimental animal models have a compressed disease course (&lt;7 days), and it is difficult to differentiate between early and late phase of infection. It would be beneficial for clinical studies to separate the early- (&lt;10 days) and late-phase (&gt;10 days) patients to determine differences in patient response between the groups.</p></sec><sec id="S3.SS2"><title>The Challenge for Therapeutic Development</title><p>Despite of the presence of a 3&#8242; to 5&#8242; exoribonuclease (exoN) proofreading enzyme, their large genome size (28&#8211;30 kb) means that CoVs remain in the category of highly mutating viruses (<xref rid="B76" ref-type="bibr">Eckerle et al., 2007</xref>, <xref rid="B75" ref-type="bibr">2010</xref>; <xref rid="B65" ref-type="bibr">Denison et al., 2011</xref>). The high mutation rate poses a considerable challenge for antiviral development as drug resistant viruses could arise or already exist within the quasispecies in nature or from an infected individual (<xref rid="B30" ref-type="bibr">Briese et al., 2014</xref>). For instance, after a prolonged period of nAb or drug treatments, the CoV can acquire mutations which confer resistance to the therapeutics (<xref rid="B287" ref-type="bibr">Zumla et al., 2016a</xref>). The appearance of these &#8220;escape viruses&#8221; has been confirmed in multiple mouse model studies in well-contained laboratory settings as well as in nature (<xref rid="B179" ref-type="bibr">Neuman et al., 2006</xref>; <xref rid="B237" ref-type="bibr">Ter Meulen et al., 2006</xref>; <xref rid="B103" ref-type="bibr">Huang et al., 2008</xref>; <xref rid="B109" ref-type="bibr">Jiang et al., 2014</xref>; <xref rid="B235" ref-type="bibr">Tang et al., 2014</xref>; <xref rid="B230" ref-type="bibr">Tai et al., 2017</xref>; <xref rid="B123" ref-type="bibr">Kleine-Weber et al., 2019</xref>). Fortunately, some of the mutations that confer drug resistance also compromise viral fitness and attenuate the virus (<xref rid="B63" ref-type="bibr">Deng et al., 2014</xref>; <xref rid="B5" ref-type="bibr">Agostini et al., 2018</xref>). Another therapeutic intervention is the use of immune modulators, such as IFN-&#945;2a/2b, IFN-&#946;1b and corticosteroids in treating CoVs (<xref rid="B149" ref-type="bibr">Loutfy et al., 2003</xref>; <xref rid="B192" ref-type="bibr">Peiris et al., 2003b</xref>; <xref rid="B229" ref-type="bibr">Sung et al., 2004</xref>). Although multiple studies have shown efficacy of IFN-&#945;2a/2b and IFN-&#946;1b singly or in combination with off-labeled antivirals such as ribavirin, lopinavir (LPV) and ritonavir (RTV) in treating SARS- and MERS-CoV in mouse, rhesus monkey and marmoset models (<xref rid="B92" ref-type="bibr">Haagmans et al., 2004</xref>; <xref rid="B19" ref-type="bibr">Barnard et al., 2006b</xref>; <xref rid="B79" ref-type="bibr">Falzarano et al., 2013b</xref>; <xref rid="B36" ref-type="bibr">Chan et al., 2015</xref>), clinical studies have shown inconclusive results (<xref rid="B173" ref-type="bibr">Momattin et al., 2013</xref>; <xref rid="B171" ref-type="bibr">Mo and Fisher, 2016</xref>). Currently, a randomized controlled trial is underway to determine the efficacy of a combination of LPV/RTV and IFN-&#946;1b in treating MERS-CoV infection (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02845843">NCT02845843</ext-link>).</p></sec><sec id="S3.SS3"><title>Convalescent Plasma and Monoclonal Antibodies</title><p>Although there is no approved drug to treat severe CoV infection, multiple strategies have shown promising results in an experimental setting (<xref ref-type="fig" rid="F2">Figure 2</xref>). Convalescent plasma (CP) is derived from patients who have recovered from SARS-CoV and MERS-CoV infection and contains high titer nAbs (<xref rid="B101" ref-type="bibr">Hsueh et al., 2004</xref>; <xref rid="B9" ref-type="bibr">Al Kahlout et al., 2019</xref>; <xref rid="B219" ref-type="bibr">Shin et al., 2019</xref>). Some data suggest that CP use against SARS-CoV infection is safe and, when administered at an early time point, may reduce mortality (<xref rid="B156" ref-type="bibr">Mair-Jenkins et al., 2015</xref>). CP neutralizing titers &gt; 1:80 may have a positive impact on infected MERS-CoV patients with respiratory failure (<xref rid="B124" ref-type="bibr">Ko et al., 2018</xref>). Unfortunately, CP from convalescent patients is difficult to obtain in large quantities and the Ab titer is too low to have beneficial effects, making it difficult to be used as a main stream therapeutic or for clinical testing (<xref rid="B15" ref-type="bibr">Arabi et al., 2016</xref>). As such, no systematic, well-designed clinical trial has formally demonstrated the efficacy of CP in emerging CoV infection. Rather, a clinical trial for testing CP against MERS-CoV infection was withdrawn prior to patient enrollment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02190799">NCT02190799</ext-link>).</p><fig id="F2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>Schematic of the CoV replication cycle and key steps for antiviral targets. White text boxes indicate the subtype of antivirals that work either extracellularly or intracellularly. Different steps of the CoV replication cycle are illustrated in cartoon form, including receptor binding, membrane fusion, viral RNA replication, sub-genomic RNA transcription and translation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-11-00658-g002.jpg"/></fig><p>Although CP from convalescent patients is difficult to obtain, the active component (neutralizing antibodies) can be isolated and subsequently produced in large quantity using recombinant technology (<xref rid="B50" ref-type="bibr">Corti et al., 2016</xref>). Passive infusion of neutralizing monoclonal Abs (mAbs) has been used for several diseases with success, including RSV and Ebola virus (<xref rid="B86" ref-type="bibr">Graham and Ambrosino, 2015</xref>; <xref rid="B289" ref-type="bibr">Zumla et al., 2016b</xref>). Numerous highly potent mAbs against SARS-CoV and MERS-CoV have been isolated by multiple groups all over the world using different methods such as phage display and direct B cell cloning from immunized animals or convalescent patients (<xref rid="B228" ref-type="bibr">Sui et al., 2004</xref>; <xref rid="B239" ref-type="bibr">Traggiai et al., 2004</xref>; <xref rid="B90" ref-type="bibr">Greenough et al., 2005</xref>; <xref rid="B244" ref-type="bibr">van den Brink et al., 2005</xref>; <xref rid="B285" ref-type="bibr">Zhu et al., 2007</xref>; <xref rid="B50" ref-type="bibr">Corti et al., 2016</xref>). While all of them shows protecting activity <italic toggle="yes">in vitro</italic>, several of them have also shown efficacy in mouse and NHP models (<xref rid="B236" ref-type="bibr">Ter Meulen et al., 2004</xref>; <xref rid="B110" ref-type="bibr">Johnson et al., 2016</xref>; <xref rid="B42" ref-type="bibr">Chen et al., 2017</xref>; <xref rid="B245" ref-type="bibr">van Doremalen et al., 2017</xref>; <xref rid="B60" ref-type="bibr">de Wit et al., 2018</xref>; <xref rid="B267" ref-type="bibr">Xu et al., 2019</xref>). The plethora of potent nAbs have also provided insight into the major antigenic sites on which vaccine development should focus. A list of mAbs that show efficacy <italic toggle="yes">in vivo</italic> against SARS-CoV and MERS-CoV are summarized in <xref rid="T2" ref-type="table">Table 2</xref>. Due to the differences in testing conditions, direct comparison of mAb efficacy should be avoided. Multiple comprehensive review articles on the subject can also be found (<xref rid="B197" ref-type="bibr">Prabakaran et al., 2009</xref>; <xref rid="B53" ref-type="bibr">Coughlin and Prabhakar, 2012</xref>; <xref rid="B267" ref-type="bibr">Xu et al., 2019</xref>).</p><table-wrap id="T2" position="float" orientation="portrait"><label>TABLE 2</label><caption><p>Summary of SAR-CoV and MERS-CoV neutralizating antibodies.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>SARS mAbs</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Epitopes</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Origins</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Animal models</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment timing, Routes</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Dose, route of infection, Strains</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Results</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">S3.1</td><td valign="top" align="left" rowspan="1" colspan="1">Spike</td><td valign="top" align="left" rowspan="1" colspan="1">EBV transformated B cell from SARS patient</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50, IN, Urbani</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung and nasal turbinates)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B239" ref-type="bibr">Traggiai et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">80R</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Phage display on naive human antibody library</td><td valign="top" align="left" rowspan="1" colspan="1">16 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50, IN, Urbani</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B228" ref-type="bibr">Sui et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">m396</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Naive human antibody library</td><td valign="top" align="left" rowspan="1" colspan="1">8 week old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, Urbani, GD03, SZ16</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B285" ref-type="bibr">Zhu et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">S230.15</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">EBV transformated B cell from SARS patient</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, Urbani, GD03, SZ16</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B285" ref-type="bibr">Zhu et al., 2007</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">12 months old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> PFU, IN, Urbani, GZ02, SZ16</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B209" ref-type="bibr">Rockx et al., 2008</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Co-administration, IN</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> PFU, IN, GZ02</td><td valign="top" align="left" rowspan="1" colspan="1">Not conclusive, reduce titer</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1, 2, and 3 days post-infection, theraputic</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> PFU, IN, GZ02</td><td valign="top" align="left" rowspan="1" colspan="1">Not protective</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CR3014</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Naive human antibody library</td><td valign="top" align="left" rowspan="1" colspan="1">Ferret</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50, IT, HKU-39849</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung), no lung lesion</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B244" ref-type="bibr">van den Brink et al., 2005</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Co-administration</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>3</sup> and 10<sup>4</sup> TCID50, IT, HKU-39849</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung), reduce lung lesion</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B236" ref-type="bibr">Ter Meulen et al., 2004</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, Urbani, GD03, SZ16</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B90" ref-type="bibr">Greenough et al., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">m68</td><td valign="top" align="left" rowspan="1" colspan="1">Spike (non-RBD)</td><td valign="top" align="left" rowspan="1" colspan="1">Transgenic mice with human Ig gene immunized with SARS-CoV Spike</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophoylatic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, Urbani, GD03, SZ16</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B90" ref-type="bibr">Greenough et al., 2005</xref></td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>MERS mAbs</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Epitopes</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Origins</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Animal models</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment timing, Routes</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Dose, route of infection, Strains</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Results</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4C2</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Mice immunized with MERS-CoV RBD</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IV</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B138" ref-type="bibr">Li et al., 2015</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">24 h post-infection, theraputic, IV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mersmab1</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Mice immunized with MERS-CoV S1</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">24 h post-infection, theraputic, IV</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4.6</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B74" ref-type="bibr">Du et al., 2014</xref>; <xref rid="B199" ref-type="bibr">Qiu et al., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CDC2-C2</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Single B cell cloning from MERS patients</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>, <xref rid="B252" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">G2</td><td valign="top" align="left" rowspan="1" colspan="1">Spike (non-RBD)</td><td valign="top" align="left" rowspan="1" colspan="1">Mice primed with MERS-CoV DNA and S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>, <xref rid="B252" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">G4</td><td valign="top" align="left" rowspan="1" colspan="1">S2</td><td valign="top" align="left" rowspan="1" colspan="1">Mice primed with MERS-CoV DNA and S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>, <xref rid="B252" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MCA1</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Phage display on naive human antibody library</td><td valign="top" align="left" rowspan="1" colspan="1">2 years old common marmosets</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#215; 10<sup>6</sup> PFU, IT, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung), weight loss and patholicical scores</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Chen et al., 2017</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2 or 12 h post-infection, theraputic, IP</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LCA60</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Single B cell cloning from MERS patients</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; 6 weeks old BALB/c transduced with hDPP4 by Ad5</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> PFU, IN, EMC/2012 and London1/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung), weight loss and pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B51" ref-type="bibr">Corti et al., 2015</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">24 h post-infection, theraputic, IP</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B51" ref-type="bibr">Corti et al., 2015</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2 &#8211; 6 years old common marmosets</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">5.2 &#215; 10<sup>6</sup> PFU, IN + IT + ocular + orally, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Moderately protective, reduce weight loss and pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B59" ref-type="bibr">de Wit et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">m336</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Phage display on navie human antibody library</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">12h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>4</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">reduce viral titer (lung), weight loss and patholicical scores</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B269" ref-type="bibr">Ying et al., 2014</xref>, <xref rid="B270" ref-type="bibr">2015</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">12h post-infection, theraputic, IP</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B7" ref-type="bibr">Agrawal et al., 2016</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">5 &#8211; 7 months old Australian white rabbit</td><td valign="top" align="left" rowspan="1" colspan="1">24 h pre-infection, prophylactic, IV and IN</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral RNA titer and lung inflammation</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B100" ref-type="bibr">Houser et al., 2016</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Common marmosets</td><td valign="top" align="left" rowspan="1" colspan="1">6 h (IV) and 48 h (SC) post-infection, theraputic</td><td valign="top" align="left" rowspan="1" colspan="1">5.2 &#215; 10<sup>6</sup> PFU, IN + IT + ocular + orally, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Moderately protective, reduce clinical diseases and gross pathology</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B245" ref-type="bibr">van Doremalen et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NbMS10</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">llama immunized with MERS-CoV RBD</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">3 days pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5.3</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce weight loss and increase survival</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B279" ref-type="bibr">Zhao et al., 2018</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1 or 3 days post-infection, theraputic, IP</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B279" ref-type="bibr">Zhao et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCAb-83</td><td valign="top" align="left" rowspan="1" colspan="1">RBD</td><td valign="top" align="left" rowspan="1" colspan="1">Dromedary camel immunized with MERS-CoV DNA and Spike protein</td><td valign="top" align="left" rowspan="1" colspan="1">hDPP4 transgenic mice</td><td valign="top" align="left" rowspan="1" colspan="1">6 h pre-infection, prophylactic, IP</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID50, IN, EMC/2012</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce viral titer (lung), weight loss and increase survival</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B202" ref-type="bibr">Raj et al., 2018</xref></td></tr></tbody></table><table-wrap-foot><attrib><italic toggle="yes">IV, intravenous; IN, intranasal; IT, intratracheal; SC, subcutaneous; IP, intraperitoneal.</italic></attrib></table-wrap-foot></table-wrap><p>The binding epitopes of some well-studied mAbs provide valuable information for the neutralization mechanism and clinical implications. The majority of the mAbs target the RBD of the spike protein and prevent viral attachment. For example, mAb 80R is able to protect both <italic toggle="yes">in vitro</italic> and a 16 weeks old mouse model against SARS-CoV Urbani. However, it is unable to protect other strains due to amino acid variations in the RBD (<xref rid="B285" ref-type="bibr">Zhu et al., 2007</xref>). On the other hand, S230.15 mimics receptor binding and triggers conformational changes in the SARS <italic toggle="yes">S</italic>-protein, completely protecting young and old mice from SARS-CoV challenge against multiple SARS-CoV, including Urbani, GD03 and SZ16 (<xref rid="B209" ref-type="bibr">Rockx et al., 2008</xref>; <xref rid="B247" ref-type="bibr">Walls et al., 2019a</xref>). Similar to SARS-CoV, the majority of mAbs targeting MERS-CoV, such as MERS-4, MERS-27 (<xref rid="B109" ref-type="bibr">Jiang et al., 2014</xref>), m336 (<xref rid="B269" ref-type="bibr">Ying et al., 2014</xref>, <xref rid="B270" ref-type="bibr">2015</xref>) and humanized Ab 4C2 and 2E6 (<xref rid="B138" ref-type="bibr">Li et al., 2015</xref>) all target the RBD and prevent the virus from binding to DPP4 with high potency. Interestingly, the mAb LCA60, isolated from a MERS-CoV infected patient, binds to RBD region and confers a broader neutralizing breadth, and is able to neutralize EMC2012 and London1 strains of MERS-CoV (<xref rid="B51" ref-type="bibr">Corti et al., 2015</xref>). Non-RBD targeting Abs G2 and G4 recognize the non-RBD region of S1 and S2 of MERS-CoV, respectively, showing cross-reactivity with multiple MERS-CoV variants and can protect hDPP4 transduced mice from challenge (<xref rid="B253" ref-type="bibr">Wang et al., 2015</xref>, <xref rid="B252" ref-type="bibr">2018</xref>). Two nanobodies isolated from camelids, NbMS10 and HCAb-83, show potency in hDPP4 transgenic mice by reducing weight loss and increasing survival after challenge. Interestingly, NbMS10 is able to protect mice as a therapeutic treatment 3 days post infection (<xref rid="B202" ref-type="bibr">Raj et al., 2018</xref>; <xref rid="B279" ref-type="bibr">Zhao et al., 2018</xref>).</p><p>While many mAbs show promising properties for clinical use, two mAbs, REGN3048 and REGN3051, have completed phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03301090">NCT03301090</ext-link>). These two mAbs were isolated from VelocImmune mice (expressing the variable regions of human Ig heavy and kappa light chain) immunized with MERS <italic toggle="yes">S</italic>-protein. Both mAbs show picomolar binding and inhibition of MERS pseudo particles transduction on Huh7 cells. REGN3048 is able to neutralize seven natural isolates of S variants, and IP injection of the mAb at 1 day before or after challenge reduces MERS-CoV RNA levels and lung pathologies in an hDPP4 transgenic mouse model (<xref rid="B187" ref-type="bibr">Pascal et al., 2015</xref>). Given the acute severe phase that is associated with emerging CoV infections, a major hurdle for therapeutic antibodies and drugs is that early administration will likely prove most efficacious in clinical care, as has also been shown with influenza virus, Ebola virus and RSV immunotherapeutics (<xref rid="B183" ref-type="bibr">Olinger et al., 2012</xref>; <xref rid="B200" ref-type="bibr">Qiu et al., 2012</xref>; <xref rid="B82" ref-type="bibr">Fry et al., 2014</xref>; <xref rid="B206" ref-type="bibr">Rezaee et al., 2017</xref>).</p></sec><sec id="S3.SS4"><title>Fusion and Viral Protease Inhibitors</title><p>Another critical step for CoV life cycle is membrane fusion and the subsequent release of the RNA genome for replication (<xref rid="B169" ref-type="bibr">Millet and Whittaker, 2018</xref>). Membrane fusion of CoVs is governed by the S2 domain of the <italic toggle="yes">S</italic>-protein (<xref rid="B186" ref-type="bibr">Pallesen et al., 2017</xref>; <xref rid="B238" ref-type="bibr">Tortorici and Veesler, 2019</xref>). The S2 stem undergoes a major conformational change at the two heptad repeat regions (HR1 and HR2) to bring the host and viral membrane in close proximity for fusion pore formation (<xref rid="B274" ref-type="bibr">Yuan et al., 2017</xref>; <xref rid="B248" ref-type="bibr">Walls et al., 2019b</xref>). Multiple peptidomimetic fusion inhibitors that mimic the HR1 and HR2 of either SARS-CoV or MERS-CoV block the formation of the helical core and efficiently inhibit membrane fusion in the micromolar range (<xref rid="B83" ref-type="bibr">Gao et al., 2013</xref>; <xref rid="B150" ref-type="bibr">Lu et al., 2014</xref>; <xref rid="B266" ref-type="bibr">Xia et al., 2019</xref>). A single report has shown treatment of HR2 peptide 5h prior to MERS-CoV challenge in an Ad5-hDPP4 transduction mouse model reduces viral lung titer (<xref rid="B40" ref-type="bibr">Channappanavar et al., 2015</xref>). The ability of these drugs to protect in lethal, high titer mouse models has yet to be proven.</p><p>CoV nsp3 and nsp5 genes encode the papain-like cysteine protease (PLpro) and 3C-like serine protease (3CLpro), respectively (<xref rid="B193" ref-type="bibr">Perlman and Netland, 2009</xref>). PLpro cleaves the polyprotein and separates it into nsp1 to 4 while 3CLpro separates nsp4 to 16 (<xref rid="B286" ref-type="bibr">Ziebuhr et al., 2000</xref>; <xref rid="B96" ref-type="bibr">Harcourt et al., 2004</xref>). Since polyprotein processing is a critical step for CoV replication and transcription, viral proteases are high priority drug targets. Originally developed as HIV protease inhibitors, LPV and RTV have low micromolar activity against 3CLpro of both SARS-CoV and MERS-CoV <italic toggle="yes">in vitro</italic> (<xref rid="B265" ref-type="bibr">Wu et al., 2004</xref>; <xref rid="B57" ref-type="bibr">De Wilde et al., 2014</xref>). Testing in SARS-CoV infected patients has shown beneficial outcomes, including lowering the viral load, reducing the onset of ARDS, and lowering mortality rates with LPV and RTV (see nucleoside analogs) treatments (<xref rid="B45" ref-type="bibr">Chu et al., 2004</xref>). However, most of the drug studies were performed using retrospective control, sometimes with unbalanced gender ratios, and no treatment has proven efficacious in a randomized control trial (<xref rid="B287" ref-type="bibr">Zumla et al., 2016a</xref>). In a marmoset model, LPV/RTV treatment suggested a modest improvement in clinical and pathological outcome as well as reduction of viral load (<xref rid="B36" ref-type="bibr">Chan et al., 2015</xref>). However, due to different pathological consequences of treated and untreated group, viral titers were measured at different time points post-infection and all the experiments were performed with a relatively small number (<italic toggle="yes">n</italic> = 3) of single gender (male) animals (<xref rid="B36" ref-type="bibr">Chan et al., 2015</xref>). SARS-CoV and MERS-CoV infection has been shown to be heavily biased by age and gender, where elders and males experience more severe complications than females in clinical cases and mouse models (<xref rid="B116" ref-type="bibr">Karlberg et al., 2004</xref>; <xref rid="B11" ref-type="bibr">Alghamdi et al., 2014</xref>; <xref rid="B39" ref-type="bibr">Channappanavar et al., 2017</xref>). A single subject in a case study, an elderly patient, survived a severe MERS-CoV infection using a combination therapy of LPV/RTV, IFN1&#945;, and ribavirin (<xref rid="B121" ref-type="bibr">Kim et al., 2016</xref>). An ongoing clinical trial in Saudi Arabia has begun to use a combination of LPV/RTV and IFN&#946;-1b for laboratory-confirmed MERS-CoV infection (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02845843">NCT02845843</ext-link>). Given the importance of 3CLpro I viral life cycle, it is an attractive target for novel drug development (<xref rid="B126" ref-type="bibr">Kumar et al., 2017</xref>).</p></sec><sec id="S3.SS5"><title>Nucleoside Analogs and RdRp Inhibitors</title><p>Ribavirin is a guanosine analog that targets RNA dependent RNA polymerases (RdRp) and has a broad efficacy against RNA viruses (<xref rid="B148" ref-type="bibr">Loustaud-Ratti et al., 2016</xref>). The drug inhibits viral RNA synthesis and has shown efficacy against HCV and RSV (<xref rid="B56" ref-type="bibr">De Clercq et al., 2016</xref>). Ribavirin inhibits SARS-CoV and MERS-CoV replication at high concentration <italic toggle="yes">in vitro</italic> (<xref rid="B232" ref-type="bibr">Tan et al., 2004</xref>; <xref rid="B78" ref-type="bibr">Falzarano et al., 2013a</xref>), However, ribavirin enhances viral replication in the mouse lung and prolongs viral persistence in a SARS-CoV mouse model (<xref rid="B18" ref-type="bibr">Barnard et al., 2006a</xref>). Although not effective as a monotherapy, ribavirin shows a synergistic effect against SARS-CoV and MERS-CoV when combine with IFN (<xref rid="B173" ref-type="bibr">Momattin et al., 2013</xref>). In a rhesus macaque model, MERS-CoV infected monkeys show improvement after treating with ribavirin and IFN-&#945;2b (<xref rid="B79" ref-type="bibr">Falzarano et al., 2013b</xref>). Furthermore, ribavirin has been used in clinical settings during SARS-CoV and MERS-CoV outbreaks (<xref rid="B184" ref-type="bibr">Omrani et al., 2014</xref>; <xref rid="B118" ref-type="bibr">Khalid et al., 2015</xref>; <xref rid="B215" ref-type="bibr">Shalhoub et al., 2015</xref>). While some studies report positive outcome after treatment with ribavirin + IFN, others suggest no significant improvement (<xref rid="B66" ref-type="bibr">Dicaro et al., 2004</xref>; <xref rid="B118" ref-type="bibr">Khalid et al., 2015</xref>). Due to the variation in dosage and time of administration and the lack of control, the efficacy of using ribavirin in patients is inconclusive. Mechanistically, studies show that recombinant CoV with a deleted proof-reading exonucleases N (ExoN) shows higher sensitivity toward ribavirin. These results indirectly suggest that the low activity of ribavirin in CoV could be explained by the presence of a proofreading exonucleases N (ExoN, nsp14) which can excise the drug from the viral mRNA in CoVs (<xref rid="B221" ref-type="bibr">Smith et al., 2013</xref>; <xref rid="B80" ref-type="bibr">Ferron et al., 2017</xref>).</p><p>Two nucleoside analogs, &#946;-<sc>D</sc>-N4-Hydroxycytidine (NHC) and GS-5734 (remdesivir), have shown high efficacy against CoVs and are less sensitive to ExoN (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>, <xref rid="B218" ref-type="bibr">2020</xref>; <xref rid="B5" ref-type="bibr">Agostini et al., 2018</xref>, <xref rid="B6" ref-type="bibr">2019</xref>). NHC is a cytidine analog and has recently been shown to inhibit multiple viruses, including influenza virus, RSV and Ebola virus (<xref rid="B205" ref-type="bibr">Reynard et al., 2015</xref>; <xref rid="B243" ref-type="bibr">Urakova et al., 2017</xref>; <xref rid="B272" ref-type="bibr">Yoon et al., 2018</xref>). It has micro-molar EC50 against both alpha and beta CoVs including SARS-CoV and MERS-CoV (<xref rid="B20" ref-type="bibr">Barnard et al., 2004</xref>; <xref rid="B198" ref-type="bibr">Pyrc et al., 2006</xref>; <xref rid="B6" ref-type="bibr">Agostini et al., 2019</xref>). Currently under clinical development for Ebola viruses, remdesivir is a nucleoside prodrug that is effective against multiple other RNA viruses including Nipah viruses, RSV, and CoVs (<xref rid="B146" ref-type="bibr">Lo et al., 2017</xref>; <xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>). Remdesivir has sub-micromolar inhibition concentrations in a broad range of CoVs including SARS-CoV, MERS-CoV, and hCoV-NL63, as well as pre-pandemic bat-CoVs WIV1 and SHC014 in an <italic toggle="yes">in vitro</italic> human airway epithelial (HAE) model (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>; <xref rid="B5" ref-type="bibr">Agostini et al., 2018</xref>). Prophylactic administration (one day pre-infection) of remdesivir can mitigate disease by reducing the viral titer and lung pathology in lethal mouse models challenged with a mouse adapted SARS-CoV MA15. Remdesivir also shows therapeutic activity when administered early at one day post-infection (corresponding to 7&#8211;10 days after the onset of symptoms in human infection). However, treatment initiated two days post infection does not improve disease outcomes, although the murine disease model is more compressed than in humans (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>). Importantly, remdesivir shows excellent prophylactic protection. Rhesus macaques are completely protected from MERS-CoV infection as scored by lung pathology and clinical score as well as inhibited viral growth. Therapeutic treatment 12-h post infection shows moderate improvement of clinical outcomes on NHPs (<xref rid="B58" ref-type="bibr">de Wit et al., 2020</xref>). The parental nucleoside of remdesivir, GS-441524, has also shown to be effective for treating FIP, a disease caused by the &#945;-CoV FIPV (<xref rid="B176" ref-type="bibr">Murphy et al., 2018</xref>; <xref rid="B190" ref-type="bibr">Pedersen et al., 2019</xref>). Currently, NHC and remdesivir are the only broadly effective antiviral drugs against all SARS-like, MERS-like, human contemporary, and animal CoVs (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>; <xref rid="B5" ref-type="bibr">Agostini et al., 2018</xref>; <xref rid="B176" ref-type="bibr">Murphy et al., 2018</xref>; <xref rid="B190" ref-type="bibr">Pedersen et al., 2019</xref>). Some antiviral drugs, such as chloroquine and T-705, also show efficacy <italic toggle="yes">in vitro</italic> and are under consideration for the current COVID-19 outbreak (<xref rid="B254" ref-type="bibr">Wang et al., 2020</xref>).</p></sec></sec><sec id="S4"><title>Host Factor Inhibitors and Immuno-Modulators</title><sec id="S4.SS1"><title>Host Protease Inhibitors</title><p>Like all class I viral fusion proteins, CoV S glycoproteins require proteolytic cleavage by host proteases for membrane fusion and viral entry (<xref rid="B22" ref-type="bibr">Belouzard et al., 2012</xref>; <xref rid="B258" ref-type="bibr">White and Whittaker, 2016</xref>; <xref rid="B169" ref-type="bibr">Millet and Whittaker, 2018</xref>). Two cleavage events have been characterized in SARS-CoV and MERS-CoV. The first cleavage event separates the head (S1) and the fusion stem (S2) by cutting the S1/S2 junction (<xref rid="B168" ref-type="bibr">Millet and Whittaker, 2015</xref>). The second cleavage event occurs at the S2&#8217; site which is usually located immediately upstream of the fusion peptide (<xref rid="B21" ref-type="bibr">Belouzard et al., 2009</xref>). Multiple proteases have been shown to be involved in the cleavage events, including cathepsin-<sc>L</sc>, trypsin-like serine proteases, transmembrane serine proteases (TTSP) and proprotein convertases such as furin (<xref rid="B168" ref-type="bibr">Millet and Whittaker, 2015</xref>). Cathepsin-<sc>L</sc> inhibitors MDL28170 and SSAA09E1 block SARS-CoV pseudotyped particle infection in pre-treated 293T cells (<xref rid="B220" ref-type="bibr">Simmons et al., 2005</xref>; <xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>). While a peptidomimetic furin substrate, decanoyl-RVKR-chloromethylketone, has been shown to inhibit cleavage of MERS <italic toggle="yes">S</italic>-protein and block infection in multiple cell lines including normal human bronchial epithelial cells (NHBE), the <italic toggle="yes">in vivo</italic> potency of this approach is less certain (<xref rid="B84" ref-type="bibr">Gierer et al., 2014</xref>; <xref rid="B167" ref-type="bibr">Millet and Whittaker, 2014</xref>; <xref rid="B159" ref-type="bibr">Matsuyama et al., 2018</xref>).</p></sec><sec id="S4.SS2"><title>Host Receptor Inhibitors</title><p>The blocking of receptor interactions is also a target of antiviral development. <italic toggle="yes">N</italic>-(2-aminoethyl)-1 aziridine-ethanamine (NAAE) blocks the interaction of SARS <italic toggle="yes">S</italic>-protein and ACE2 and inhibits S-mediated cell-to-cell fusion at millimolar concentrations (<xref rid="B104" ref-type="bibr">Huentelman et al., 2004</xref>). Similarly, an Ab blocking DPP4 can also inhibit MERS-CoV infection on primary bronchial epithelial cells (<xref rid="B201" ref-type="bibr">Raj et al., 2013</xref>). Importantly, the <italic toggle="yes">S</italic>-proteins of SARS-CoVs and MERS-CoV interact with their receptors outside of the active sites. Therefore, it would be of interest to develop inhibitors that do not affect the normal function of the host proteins but abolish the interaction of the CoV and receptor. Otherwise, long term inhibition of cellular proteins could have adverse effects on the host. For instance, inhibition of ACE2 may cause hypertension (<xref rid="B55" ref-type="bibr">Danilczyk and Penninger, 2006</xref>). Additionally, DPP4 is also responsible for multiple cellular functions including immune homeostasis, stem cell development, metabolism and T-cell regulation, and hence is not an ideal target for MERS-CoV infection (<xref rid="B160" ref-type="bibr">Matteucci and Giampietro, 2016</xref>; <xref rid="B185" ref-type="bibr">Ou et al., 2019</xref>).</p></sec><sec id="S4.SS3"><title>Other Host Factor Inhibitors</title><p>Another attractive target to inhibit CoV infection is the host metabolic pathways essential for CoV life cycles. CoVs replicate and transcribe in membrane-bound vesicles derived from the host&#8217;s rough ER (<xref rid="B222" ref-type="bibr">Snijder et al., 2006</xref>; <xref rid="B226" ref-type="bibr">Stertz et al., 2007</xref>; <xref rid="B204" ref-type="bibr">Reggiori et al., 2010</xref>). MERS-CoV infection upregulates the biosynthetic pathways of multiple major lipogenic enzymes, including fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) and HMG-CoA synthase (HMGCS) (<xref rid="B273" ref-type="bibr">Yuan et al., 2019</xref>). AM580, which targets the major lipid biosynthesis transactivator n-SREBPs by interfering with and downregulating global lipid synthesis (<xref rid="B85" ref-type="bibr">Goldstein et al., 2006</xref>; <xref rid="B273" ref-type="bibr">Yuan et al., 2019</xref>), inhibits the replication of multiple viruses including influenza virus, Zika virus, Enterovirus-A71 and MERS-CoV (<xref rid="B273" ref-type="bibr">Yuan et al., 2019</xref>). Remarkably, MERS-CoV viral titer is reduced by 1,000- to 1,000,000-fold in the presence of AM580 in Huh7 cells or a human intestinal organoid model, respectively, and IP injection of AM580 for 3 days protects a human hDPP4 transgenic mouse model from MERS-CoV lethal challenge (<xref rid="B273" ref-type="bibr">Yuan et al., 2019</xref>).</p></sec><sec id="S4.SS4"><title>Immune Modulators</title><sec id="S4.SS4.SSS1"><title>Corticosteroids</title><p>SARS-CoV and MERS-CoV both cause lung inflammation and can progress into severe respiratory syndrome. Lacking direct antiviral effect, corticosteroids are an immune suppressor which is administrated to severe patients to alleviate lung inflammation. However, immune suppression could also facilitate viral replication. Therefore, corticosteroids are often administrated with antiviral or other immune modulators, such as IFN which can activate the immune system. Retrospective and prospective clinical studies have shown mixed observation in treating SARS-CoV and MERS-CoV patients with corticosteroids, IFN and ribavirin; while some showed a positive effect, others showed no difference.</p></sec><sec id="S4.SS4.SSS2"><title>IFNs</title><p>SARS-CoV and MERS-CoV are able to suppress the induction of IFN synthesis by multiple mechanisms including inhibition of the IFN signal transduction pathways and evading detection by pattern recognition receptors (PRRs) and toll-like receptors (TLRs) (<xref rid="B81" ref-type="bibr">Frieman et al., 2008</xref>; <xref rid="B139" ref-type="bibr">Lim et al., 2016</xref>; <xref rid="B174" ref-type="bibr">Mubarak et al., 2019</xref>). Therefore, external administration of IFN regiments could re-initiate the antiviral immune response in the host. During the SARS-CoV and MERS-CoV outbreaks, IFN-&#945;, IFN-&#946;, and IFN-&#947; were used in combination with various antiviral drugs, including LPV/RTV, ribavirin, corticosteroids and poly I:C (<xref rid="B287" ref-type="bibr">Zumla et al., 2016a</xref>). Although most of the clinical reports are positive, there is no consensus on the efficacy of IFN treatment in CoV infection. In animal model studies, IFN treatment is only effective when administrated at early time point for both SARS-CoV and MERS-CoV (<xref rid="B37" ref-type="bibr">Channappanavar et al., 2016</xref>, <xref rid="B38" ref-type="bibr">2019</xref>). Furthermore, many of the clinical studies were confounded by multiple factors, including IFN dosages, combination of different antivirals, and the stage of infection (<xref rid="B171" ref-type="bibr">Mo and Fisher, 2016</xref>). For instance, some studies targeted patients in the late stage of infection and show a worse survival rate than average (<xref rid="B14" ref-type="bibr">Al-Tawfiq et al., 2014</xref>; <xref rid="B119" ref-type="bibr">Khalid et al., 2014</xref>). Based on multiple research reports, IFN-&#946; shows the best efficacy in treating MERS-CoV infection (<xref rid="B35" ref-type="bibr">Chan et al., 2013</xref>; <xref rid="B97" ref-type="bibr">Hart et al., 2014</xref>; <xref rid="B121" ref-type="bibr">Kim et al., 2016</xref>). Currently, an open labeled, well controlled clinical study is aiming to test a set dose of LPV/RTV and IFN-&#946; in treating MERS-CoV. The trial will probably provide insight into treating MERS-CoV infection in human population.</p></sec></sec></sec><sec id="S5"><title>The Current Sars-CoV-2 Outbreak: a Challenge, an Opportunity</title><p>In December 2019, a new CoV outbreak started in Wuhan, China, a megacity with a population of 11 million. With an estimated basic reproduction number (R<sub>0</sub>) of 1.4 &#8211; 2.5, SARS-CoV-2 quickly spread to every province in China and began to spread globally by the end of January 2020 (<xref rid="B284" ref-type="bibr">Zhou et al., 2020</xref>), and was declared a worldwide pandemic in March 2020 by the World Health Organization. SARS-CoV-2 is capable of human-to-human transmission via either symptomatic or asymptomatic patients (<xref rid="B210" ref-type="bibr">Rothe et al., 2020</xref>). The high mutation rate of CoVs and the possibility of super-spreader could potentiate the continuous spreading globally. Originally from bat, the SARS-CoV-2 Is 96% identical to a bat CoV designated RaTG13, isolated from a cave in Yunnan Province, China and belongs to the betacoronavirus 2b family, as does SARS-CoV (<xref rid="B284" ref-type="bibr">Zhou et al., 2020</xref>). However, the <italic toggle="yes">S</italic>-proteins between SARS-CoV and 2019 nCoV share only 76&#8211;78% sequence similarity, rendering the current experimental vaccines and antivirals unlikely to be fully protective against SARS-CoV-2. As many group 2b SARS-like CoV have pre-epidemic potential, vaccines and countermeasures should be targeted against all of these strains to maximally protect against current and future threats to the global health and economy (<xref rid="B164" ref-type="bibr">Menachery et al., 2015</xref>, <xref rid="B166" ref-type="bibr">2016</xref>).</p><p>After two CoV outbreaks in the last two decades, the public health officials and clinicians have experience in preventing spread and treating SARS-CoV-2 patients. Prompt communication between governments, quick quarantine procedures, and rapid viral detection assays have helped minimize SARS-CoV-2 cases in other countries thus far. Additionally, the scientific community has developed novel vaccine strategies and experimental antivirals to fight emerging CoV. New vaccines that specifically targeting SARS-CoV-2 are under development. Moderna had started a phase 1 clinical trial on an RNA vaccine (mRNA-1273) that encodes the prefusion stabilized form of SARS-CoV-2 <italic toggle="yes">S</italic>-protein (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>). Although there are no published studies of a RNA vaccine platform against CoV, the RNA platform has shown efficacy against multiple other viral infectious diseases including influenza, rabies, Flavivirus, and Ebola viruses in experimental animal models (<xref rid="B276" ref-type="bibr">Zhang et al., 2019</xref>). Furthermore, pre-clinical data of the Zika virus mRNA vaccine (mRNA-1893) from Moderna has shown protection against Zika virus and abrogated maternal transmission of Zika virus in pregnant mice (<xref rid="B207" ref-type="bibr">Richner et al., 2017</xref>; <xref rid="B107" ref-type="bibr">Jagger et al., 2019</xref>). Broad-spectrum antivirals which have shown efficacy against multiple CoVs have the potential to treat SARS-CoV-2 (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>, <xref rid="B218" ref-type="bibr">2020</xref>). Given the high number of infected patients and at risk individuals, the current situation provides an opportunity to initiate clinical trials for (a) vaccine formulation designed to protect uninfected people, (b) broad spectrum antivirals to treat infected individuals and (c) formulation of immune modulators to alleviate clinical pathologies. A well-designed clinical trial could not only ameliorate the current situation, but also lay the foundation for future CoV outbreaks. Supported by a recent study on SARS-CoV-2 (<xref rid="B254" ref-type="bibr">Wang et al., 2020</xref>) and multiple research studies on SARS and MERS-CoVs (<xref rid="B217" ref-type="bibr">Sheahan et al., 2017</xref>, <xref rid="B218" ref-type="bibr">2020</xref>; <xref rid="B58" ref-type="bibr">de Wit et al., 2020</xref>) and a single clinical report (<xref rid="B99" ref-type="bibr">Holshue et al., 2020</xref>), remdesivir hold promises as treatment for SARS-CoV-2. The Chinese government has started a clinical trial using remdesivir for treating SARS-CoV-2 patients with mild to severe symptoms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04252664">NCT04252664</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04257656">NCT04257656</ext-link>). On the clinical side, if time and resources permit, a centralized repository that records and digitizes infection cases would aid future medical and epidemiology studies through machine learning programs. Finally, the current situation also provides an opportunity to develop unconventional treatments, such as gene therapy, to target infectious diseases.</p></sec><sec id="S6"><title>Unconventional Vaccines and Therapeutics &#8211; Gene Therapies</title><p>The field of gene therapy has undergone rapid growth in the last 10 years. Although mainly focused on rare genetic diseases, its potential in treating infectious diseases should not be discounted. One of the leading vectors, adeno-associated virus (AAV), has proven to be safe for human use and multiple AAV-based gene therapy drugs are approved by the FDA and the EMA (<xref rid="B117" ref-type="bibr">Kay et al., 2000</xref>; <xref rid="B115" ref-type="bibr">Kaplitt et al., 2007</xref>). So far, the only report of use of AAV in CoV is as a DNA vaccine to deliver SARS-CoV spike protein for immunization (<xref rid="B73" ref-type="bibr">Du et al., 2008</xref>). Given the recent developments in human antibody cloning technologies, AAV holds a promising potential to be a hybrid of vaccine and therapeutic which acts as a passive immunization vector to provide protection for the outbreak and as a therapeutic in early time scales.</p><sec id="S6.SS1"><title>AAV as a Vector for Passive Immunization Against Emerging CoV</title><sec id="S6.SS1.SSS1"><title>The Vectors &#8211; Safety</title><p>AAV is a non-pathogenic, non-enveloped, 4.7 kb single-stranded DNA virus belonging to the <italic toggle="yes">Dependoparvovirus</italic> genus within the family <italic toggle="yes">Parvoviridae</italic> (<xref rid="B52" ref-type="bibr">Cotmore et al., 2014</xref>). AAV infects a wide variety of animals, from bearded dragons to humans. Natural AAV isolates have different tissue tropisms in humans and can be reverse engineered to better fulfill various medical needs. To target SARS-CoV, MERS-CoV and other respiratory virus infections, a human airway tropic AAV is needed. Multiple reports have demonstrated that natural isolates AAV5 (<xref rid="B275" ref-type="bibr">Zabner et al., 2000</xref>), AAV6 (<xref rid="B142" ref-type="bibr">Limberis et al., 2009</xref>), and AAV9 (<xref rid="B1" ref-type="bibr">Adam et al., 2014</xref>) as well as engineered vectors AAV2.5 (<xref rid="B137" ref-type="bibr">Li et al., 2009</xref>) and AAV2.5T (<xref rid="B77" ref-type="bibr">Excoffon et al., 2009</xref>) are able to transduce human lung epithelial cells, including primary human airway epithelial (HAE) cultures. Although there is a high prevalence of nAbs against AAVs in the human population, new technologies have been developed to engineer AAV to evade humoral immune responses (<xref rid="B241" ref-type="bibr">Tse et al., 2015</xref>, <xref rid="B240" ref-type="bibr">2017</xref>). These developments potentially allow for the delivery of CoV vaccines or immunotherapeutic directly to the mucosal compartments of the lung.</p></sec><sec id="S6.SS1.SSS2"><title>The Package &#8211; Flexibility</title><p>Passive immunization of AAV can be developed as a platform technology in which the nAb can be quickly exchanged to target specific pathogens. Multiple studies have shown passive immunization using AAV is effective against viral infectious diseases such as HIV, (<xref rid="B17" ref-type="bibr">Balazs et al., 2012</xref>; <xref rid="B143" ref-type="bibr">Lin and Balazs, 2018</xref>) Ebola, (<xref rid="B141" ref-type="bibr">Limberis et al., 2016</xref>) influenza, (<xref rid="B16" ref-type="bibr">Balazs et al., 2013</xref>; <xref rid="B132" ref-type="bibr">Laursen et al., 2018</xref>), and others (<xref rid="B180" ref-type="bibr">Nieto and Salvetti, 2014</xref>). The package for delivery is extremely flexible, from authentic immunoglobulins (IgG) to immunoadhesins (IA) to single chain variable fragments (scFv) to bi-specific antibodies (<xref rid="B178" ref-type="bibr">Naso et al., 2017</xref>). Furthermore, a combination of Abs, small antiviral peptides and immuno-modulators can be co-delivered at the same time to achieve multidimensional therapy. Although AAV-based passive immunization has not yet been tested as therapeutic, it could serve as a fast-acting prophylactic alternative to traditional vaccines.</p></sec><sec id="S6.SS1.SSS3"><title>The Timing &#8211; Quick</title><p>The most important aspect to control an outbreak is to reduce the spread by protecting the population from infection. However, there is a lag time between the beginning of an outbreak and the development of an effective vaccine in which the population is completely vulnerable. Prophylactic treatments, such as infusion of Abs and antivirals, could protect individual for a short duration. However, these prophylactic treatments require constant intake to stay effective and are toxic as well as financially impractical for long-term use (<xref rid="B94" ref-type="bibr">Hansel et al., 2010</xref>). AAV-based passive immunization could perfectly fill the vacuum by protecting the population before the arrival of a vaccine. Since AAV is a platform technology, anti-viral packages can be swapped and tested quickly, within a month (<xref rid="B227" ref-type="bibr">Strobel et al., 2019</xref>). After administration in animals, protection can be achieved in less than a week, faster than any vaccine strategies. In an influenza study, AAV9 delivery of IA via intranasal inoculation protected animals from lethal influenza challenges including H5N1, H1N1 and H1N1 1918 within 3 days of AAV administration (<xref rid="B140" ref-type="bibr">Limberis et al., 2013</xref>). Unlike traditional gene therapy in which the transgene lasts for long periods of time, the natural turnover rate of airway epithelia means that the nAb introduction is not permanent, reducing the chance that the host will produce antibodies targeting the therapeutic antibody delivered by AAV (anti-drug antibody responses) (<xref rid="B180" ref-type="bibr">Nieto and Salvetti, 2014</xref>). Therefore, AAV-based passive immunization is a quick and excellent option to deploy in an outbreak situation for emerging infectious diseases.</p></sec></sec><sec id="S6.SS2"><title>The Challenges</title><p>AAV-based gene therapy has great potential for treating viral infectious diseases. However, there are multiple hurdles for AAV-based gene therapy to achieve its full potential. (1) Low transduction efficiency, (2) pre-existing nAb against AAVs, (3) transgene toxicity and loss of expression, and (4) extremely high price tag (<xref rid="B46" ref-type="bibr">Colella et al., 2018</xref>; <xref rid="B111" ref-type="bibr">Kaemmerer, 2018</xref>). Fortunately, multiple strategies have been developed to address these hurdles (<xref rid="B241" ref-type="bibr">Tse et al., 2015</xref>). For instance, through vector engineering, a new generation of AAV vectors can evade pre-existing nAbs while retaining a good transduction profile in the respiratory system (<xref rid="B137" ref-type="bibr">Li et al., 2009</xref>; <xref rid="B240" ref-type="bibr">Tse et al., 2017</xref>). For rare genetic diseases, life-long gene expression is important for therapeutic purposes but could cause toxicity. On the contrary, for emerging CoVs, the goal is a short-term protection from the virus. Therefore, AAV can target epithelial cells that have a regular turn-over rate, hence providing short-term protection and preventing transgene toxicity. AAV-based therapies are known for their extremely high prices, sometime up to a million US dollar per treatment. However, the prices are inflated due to the small market size of rare genetic diseases and the cost for drug development. Given the huge market size of infectious diseases, the price for AAV-based therapy for infectious diseases should be more reasonable. Unlike rare genetic diseases and other infectious diseases, an emerging CoV outbreak is uniquely suitable for AAV-based passive immunization as a short-term protection therapy before vaccine deployment.</p></sec></sec><sec id="S7"><title>Conclusion</title><p>The continuous development of vaccines, antivirals, and hopefully gene therapies will provide an arsenal for combating and controlling emerging CoV diseases. For vaccine development, understanding the antigenicity and neutralizing antibody footprints of different CoVs could aid the development of broad-spectrum vaccines and, ultimately, the possibility of a universal CoV vaccine. Vaccine formulation, including dosage and adjuvants, should be tested systemically and, if possible, on animal models that reflects the genetic variation of the human population. A deeper understanding of the basic biology of CoV and host-virus interaction can lead to the discovery of druggable targets. Importantly, we should not overlook the potential of the existing broad-spectrum antivirals and should start clinical trials on these drugs in a timely fashion. Prevention is always the best treatment, and constant viral surveillance of wild animals for potential emerging CoVs is extremely important. Testing the outbreak potential of heterologous SARS- and MERS-like viruses with different spike proteins could better prepare society from the next outbreak. A centralized digital database that collect public health and clinical information of the current outbreak would allow global retrospective studies in the future using machine learning and other big data analysis. On the research side, quick, reliable and easily employed viral testing kits should be developed. Innovative technologies such as gene therapy should be adequately explored for their potential to combat CoVs and act as another line of defense against elusive emerging viral diseases. The current SARS-CoV-2 poses a huge challenge for society; however, given experience with emerging CoVs and global effort, it is hoped that the impact of the outbreak will be minimal.</p></sec><sec id="S8"><title>Author Contributions</title><p>LT wrote the review. RM, RG, and RB reviewed and revised the final version.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The manuscript presented here were supported by grants from the National Institute of Allergy and Infectious Disease of the United States National Institutes of Health (NIH) by awards AI108197, AI110700, AI132178, and AI149644 (RB). <xref ref-type="fig" rid="F2">Figure 2</xref> is generated using biorender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link>).</p></fn></fn-group><ack><p>We thank Dr. Timothy Sheahan and Dr. Yixuan Hou for critical reading of this manuscript and all members in the RB laboratory for helpful discussions.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Crosariol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>M. Q.</given-names></name><name name-style="western"><surname>Czack</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus.</article-title><source><italic toggle="yes">Clin. Vaccine Immunol.</italic></source><volume>21</volume><fpage>1528</fpage>&#8211;<lpage>1533</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00572-514</pub-id><pub-id pub-id-type="pmid">25209558</pub-id><pub-id pub-id-type="pmcid">PMC4248762</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adedeji</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Severson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Sarafianos</surname><given-names>S. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>87</volume><fpage>8017</fpage>&#8211;<lpage>8028</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00998-913</pub-id><pub-id pub-id-type="pmid">23678171</pub-id><pub-id pub-id-type="pmcid">PMC3700180</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adney</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>11</volume>:<issue>212</issue>. <pub-id pub-id-type="doi">10.3390/v11030212</pub-id><pub-id pub-id-type="pmid">30832356</pub-id><pub-id pub-id-type="pmcid">PMC6466352</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gopal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L. J.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>209</volume><fpage>995</fpage>&#8211;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit609</pub-id><pub-id pub-id-type="pmid">24253287</pub-id><pub-id pub-id-type="pmcid">PMC3952667</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agostini</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Andres</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease.</article-title><source><italic toggle="yes">mBio</italic></source><volume>9</volume><fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00221-218</pub-id><pub-id pub-id-type="pmcid">PMC5844999</pub-id><pub-id pub-id-type="pmid">29511076</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agostini</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Pruijssers</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Gribble</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Andres</surname><given-names>E. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Small-molecule antiviral &#946;-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>93</volume>:<issue>e01348-19</issue><pub-id pub-id-type="doi">10.1128/JVI.01348-1319</pub-id><pub-id pub-id-type="pmcid">PMC6880162</pub-id><pub-id pub-id-type="pmid">31578288</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B. H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.</article-title><source><italic toggle="yes">Hum. Vaccines Immunother.</italic></source><volume>12</volume><fpage>2351</fpage>&#8211;<lpage>2356</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmid">27269431</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>A. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Diagnostic delays in Middle East respiratory syndrome coronavirus patients and health systems.</article-title><source><italic toggle="yes">J. Infect. Public Health</italic></source><volume>12</volume><fpage>767</fpage>&#8211;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2019.04.002</pub-id><pub-id pub-id-type="pmid">31006635</pub-id><pub-id pub-id-type="pmcid">PMC7102677</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Kahlout</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Farag</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lattwein</surname><given-names>E.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Comparative serological study for the prevalence of Anti-MERS coronavirus antibodies in high- and low-risk groups in qatar.</article-title><source><italic toggle="yes">J. Immunol. Res.</italic></source><volume>2019</volume>:<issue>1386740</issue>. <pub-id pub-id-type="doi">10.1155/2019/1386740</pub-id><pub-id pub-id-type="pmid">30906787</pub-id><pub-id pub-id-type="pmcid">PMC6398027</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Amri</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Siddiq</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanki</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Al-Muhanna</surname><given-names>M. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>7</volume>:<issue>44875</issue>. <pub-id pub-id-type="doi">10.1038/srep44875</pub-id><pub-id pub-id-type="pmid">28332568</pub-id><pub-id pub-id-type="pmcid">PMC5362948</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alghamdi</surname><given-names>I. G.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>I. I.</given-names></name><name name-style="western"><surname>Almalki</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>El-Sheemy</surname><given-names>M. A.</given-names></name></person-group> (<year>2014</year>). <article-title>The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health.</article-title><source><italic toggle="yes">Int. J. Gen. Med.</italic></source><volume>7</volume><fpage>417</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.2147/IJGM.S67061</pub-id><pub-id pub-id-type="pmid">25187734</pub-id><pub-id pub-id-type="pmcid">PMC4149400</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alharbi</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Padron-Regalado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>35</volume><fpage>3780</fpage>&#8211;<lpage>3788</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.032</pub-id><pub-id pub-id-type="pmid">28579232</pub-id><pub-id pub-id-type="pmcid">PMC5516308</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almaz&#225;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dediego</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zu&#241;iga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nieto-torres</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Marquez-jurado</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A Vaccine candidate east respiratory syndrome coronavirus as a vaccine candidate.</article-title><source><italic toggle="yes">mBio</italic></source><volume>4</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00650-13.Editor</pub-id><pub-id pub-id-type="pmcid">PMC3774192</pub-id><pub-id pub-id-type="pmid">24023385</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Momattin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dib</surname><given-names>J.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.</article-title><source><italic toggle="yes">Int. J. Infect. Dis.</italic></source><volume>20</volume><fpage>42</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.12.003</pub-id><pub-id pub-id-type="pmid">24406736</pub-id><pub-id pub-id-type="pmcid">PMC7110882</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Hajeer</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johani</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia.</article-title><source><italic toggle="yes">Emerg. Infect. Dis.</italic></source><volume>22</volume><fpage>1554</fpage>&#8211;<lpage>1561</lpage>. <pub-id pub-id-type="doi">10.3201/eid2209.151164</pub-id><pub-id pub-id-type="pmid">27532807</pub-id><pub-id pub-id-type="pmcid">PMC4994343</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balazs</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Broad protection against influenza infection by vectored immunoprophylaxis in mice.</article-title><source><italic toggle="yes">Nat. Biotechnol.</italic></source><volume>31</volume>:<issue>647</issue>. <pub-id pub-id-type="doi">10.1038/nbt.2618</pub-id><pub-id pub-id-type="pmid">23728362</pub-id><pub-id pub-id-type="pmcid">PMC4030719</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balazs</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Antibody-based protection against HIV infection by vectored immunoprophylaxis.</article-title><source><italic toggle="yes">Nature</italic></source><volume>481</volume><fpage>81</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/nature10660</pub-id><pub-id pub-id-type="pmid">22139420</pub-id><pub-id pub-id-type="pmcid">PMC3253190</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lauridsen</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2006a</year>). <article-title>Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>71</volume><fpage>53</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.03.001</pub-id><pub-id pub-id-type="pmid">16621037</pub-id><pub-id pub-id-type="pmcid">PMC7114261</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lauridsen</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2006b</year>). <article-title>Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice.</article-title><source><italic toggle="yes">Antivir. Chem. Chemother.</italic></source><volume>17</volume><fpage>275</fpage>&#8211;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1177/095632020601700505</pub-id><pub-id pub-id-type="pmid">17176632</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smee</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Morrey</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and &#946;-D-N4-hydroxycytidine.</article-title><source><italic toggle="yes">Antivir. Chem. Chemother.</italic></source><volume>15</volume><fpage>15</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1177/095632020401500102</pub-id><pub-id pub-id-type="pmid">15074711</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belouzard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>106</volume><fpage>5871</fpage>&#8211;<lpage>5876</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809524106</pub-id><pub-id pub-id-type="pmid">19321428</pub-id><pub-id pub-id-type="pmcid">PMC2660061</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belouzard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Millet</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>4</volume><fpage>1011</fpage>&#8211;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.3390/v4061011</pub-id><pub-id pub-id-type="pmid">22816037</pub-id><pub-id pub-id-type="pmcid">PMC3397359</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belshe</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Mendelman</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reisinger</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>181</volume><fpage>1133</fpage>&#8211;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1086/315323</pub-id><pub-id pub-id-type="pmid">10720541</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binnie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>J. L. Y.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>C. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Biomarkers in acute respiratory distress syndrome.</article-title><source><italic toggle="yes">Curr. Opin. Crit. Care</italic></source><volume>20</volume><fpage>47</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0000000000000048</pub-id><pub-id pub-id-type="pmid">24296379</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B. R.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>101</volume><fpage>6641</fpage>&#8211;<lpage>6646</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0401939101</pub-id><pub-id pub-id-type="pmid">15096611</pub-id><pub-id pub-id-type="pmcid">PMC404098</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group> (<year>2005</year>). <article-title>Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein.</article-title><source><italic toggle="yes">Virology</italic></source><volume>334</volume><fpage>160</fpage>&#8211;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2005.01.042</pub-id><pub-id pub-id-type="pmid">15780866</pub-id><pub-id pub-id-type="pmcid">PMC7111832</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodmer</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Hanauer</surname><given-names>J. R. H.</given-names></name><name name-style="western"><surname>M&#252;hlebach</surname><given-names>M. D.</given-names></name></person-group> (<year>2018</year>). <article-title>Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.</article-title><source><italic toggle="yes">Virology</italic></source><volume>521</volume><fpage>99</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2018.05.028</pub-id><pub-id pub-id-type="pmid">29902727</pub-id><pub-id pub-id-type="pmcid">PMC7118890</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Long</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011a</year>). <article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>85</volume><fpage>12201</fpage>&#8211;<lpage>12215</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.06048-6011</pub-id><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.</given-names></name></person-group> (<year>2011b</year>). <article-title>SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission.</article-title><source><italic toggle="yes">Curr. Opin. Virol.</italic></source><volume>1</volume><fpage>624</fpage>&#8211;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2011.10.012</pub-id><pub-id pub-id-type="pmid">22180768</pub-id><pub-id pub-id-type="pmcid">PMC3237677</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briese</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>K.</given-names></name><name name-style="western"><surname>East</surname><given-names>M.</given-names></name><name name-style="western"><surname>Syndrome</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quasispecies</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Dromedary camels in Saudi Arabia include homologues of human isolates revealed through whole-genome analysis etc.</article-title><source><italic toggle="yes">mBio</italic></source><volume>5</volume><fpage>1</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.01146-14.Editor</pub-id><pub-id pub-id-type="pmcid">PMC4010836</pub-id><pub-id pub-id-type="pmid">24781747</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>U. J.</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>101</volume><fpage>9804</fpage>&#8211;<lpage>9809</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403492101</pub-id><pub-id pub-id-type="pmid">15210961</pub-id><pub-id pub-id-type="pmcid">PMC470755</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bukreyev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U. J.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>St Claire</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Mucosal immunisation of African green monkeys (<italic toggle="yes">Cercopithecus aethiops</italic>) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>363</volume><fpage>2122</fpage>&#8211;<lpage>2127</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16501-X</pub-id><pub-id pub-id-type="pmid">15220033</pub-id><pub-id pub-id-type="pmcid">PMC7112367</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabe&#231;a</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Granato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bellei</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>). <article-title>Epidemiological and clinical features of human coronavirus infections among different subsets of patients.</article-title><source><italic toggle="yes">Influenza Other Respir. Viruses</italic></source><volume>7</volume><fpage>1040</fpage>&#8211;<lpage>1047</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12101</pub-id><pub-id pub-id-type="pmid">23462106</pub-id><pub-id pub-id-type="pmcid">PMC4634278</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bermejo-Martin</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>81</volume><fpage>8692</fpage>&#8211;<lpage>8706</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00527-527</pub-id><pub-id pub-id-type="pmid">17537853</pub-id><pub-id pub-id-type="pmcid">PMC1951379</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F. W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>R. Y. T.</given-names></name><name name-style="western"><surname>To</surname><given-names>K. K. W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. P. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">J. Infect.</italic></source><volume>67</volume><fpage>606</fpage>&#8211;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2013.09.029</pub-id><pub-id pub-id-type="pmid">24096239</pub-id><pub-id pub-id-type="pmcid">PMC7112612</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F. W.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Treatment with lopinavir/ritonavir or interferon-&#946;1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>212</volume><fpage>1904</fpage>&#8211;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id><pub-id pub-id-type="pmid">26198719</pub-id><pub-id pub-id-type="pmcid">PMC7107395</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Vijay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice.</article-title><source><italic toggle="yes">Cell Host Microbe</italic></source><volume>19</volume><fpage>181</fpage>&#8211;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><pub-id pub-id-type="pmid">26867177</pub-id><pub-id pub-id-type="pmcid">PMC4752723</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abrahante</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.</article-title><source><italic toggle="yes">J. Clin. Invest.</italic></source><volume>129</volume><fpage>3625</fpage>&#8211;<lpage>3639</lpage>. <pub-id pub-id-type="doi">10.1172/JCI126363</pub-id><pub-id pub-id-type="pmid">31355779</pub-id><pub-id pub-id-type="pmcid">PMC6715373</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ten Eyck</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection.</article-title><source><italic toggle="yes">J. Immunol.</italic></source><volume>198</volume><fpage>4046</fpage>&#8211;<lpage>4053</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1601896</pub-id><pub-id pub-id-type="pmid">28373583</pub-id><pub-id pub-id-type="pmcid">PMC5450662</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Protective effect of intranasal regimens containing peptidic middle east respiratory syndrome coronavirus fusion Inhibitor against MERS-CoV infection.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>212</volume><fpage>1894</fpage>&#8211;<lpage>1903</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv325</pub-id><pub-id pub-id-type="pmid">26164863</pub-id><pub-id pub-id-type="pmcid">PMC4655857</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>T cell-mediated immune response to respiratory coronaviruses.</article-title><source><italic toggle="yes">Immunol. Res.</italic></source><volume>59</volume><fpage>118</fpage>&#8211;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-014-8534-z</pub-id><pub-id pub-id-type="pmid">24845462</pub-id><pub-id pub-id-type="pmcid">PMC4125530</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>215</volume><fpage>1807</fpage>&#8211;<lpage>1815</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix209</pub-id><pub-id pub-id-type="pmid">28472421</pub-id><pub-id pub-id-type="pmcid">PMC7107363</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>35</volume><fpage>2069</fpage>&#8211;<lpage>2075</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.063</pub-id><pub-id pub-id-type="pmid">28314561</pub-id><pub-id pub-id-type="pmcid">PMC5411280</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chirmule</surname><given-names>N.</given-names></name><name name-style="western"><surname>Propert</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Magosin</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Immune responses to adenovirus and adeno-associated virus in humans.</article-title><source><italic toggle="yes">Gene Ther.</italic></source><volume>6</volume><fpage>1574</fpage>&#8211;<lpage>1583</lpage>. <pub-id pub-id-type="doi">10.1038/sj.gt.3300994</pub-id><pub-id pub-id-type="pmid">10490767</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V. C. C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I. F. N.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M. M. L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.</article-title><source><italic toggle="yes">Thorax</italic></source><volume>59</volume><fpage>252</fpage>&#8211;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><pub-id pub-id-type="pmid">14985565</pub-id><pub-id pub-id-type="pmcid">PMC1746980</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colella</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ronzitti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Emerging Issues in AAV-Mediated In Vivo Gene Therapy.</article-title><source><italic toggle="yes">Mol. Ther. Methods Clin. Dev.</italic></source><volume>8</volume><fpage>87</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtm.2017.11.007</pub-id><pub-id pub-id-type="pmid">29326962</pub-id><pub-id pub-id-type="pmcid">PMC5758940</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D. C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>32</volume><fpage>3169</fpage>&#8211;<lpage>3174</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D. C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>35</volume><fpage>1586</fpage>&#8211;<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.012</pub-id><pub-id pub-id-type="pmid">28237499</pub-id><pub-id pub-id-type="pmcid">PMC5423355</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Albarrak</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Omrani</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Albarrak</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Almasri</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection.</article-title><source><italic toggle="yes">Clin. Infect. Dis.</italic></source><volume>62</volume><fpage>477</fpage>&#8211;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ951</pub-id><pub-id pub-id-type="pmid">26565003</pub-id><pub-id pub-id-type="pmcid">PMC7108065</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Passini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zambon</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.</article-title><source><italic toggle="yes">J. Infect. Public Health</italic></source><volume>9</volume><fpage>231</fpage>&#8211;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2016.04.003</pub-id><pub-id pub-id-type="pmid">27102927</pub-id><pub-id pub-id-type="pmcid">PMC7102728</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simonelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>112</volume><fpage>10473</fpage>&#8211;<lpage>10478</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1510199112</pub-id><pub-id pub-id-type="pmid">26216974</pub-id><pub-id pub-id-type="pmcid">PMC4547275</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotmore</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Agbandje-McKenna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiorini</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Mukha</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Pintel</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The family Parvoviridae.</article-title><source><italic toggle="yes">Arch. Virol.</italic></source><volume>159</volume><fpage>1239</fpage>&#8211;<lpage>1247</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-013-1914-1911</pub-id><pub-id pub-id-type="pmid">24212889</pub-id><pub-id pub-id-type="pmcid">PMC4013247</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coughlin</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Prabhakar</surname><given-names>B. S.</given-names></name></person-group> (<year>2012</year>). <article-title>Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.</article-title><source><italic toggle="yes">Rev. Med. Virol.</italic></source><volume>22</volume><fpage>2</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.706</pub-id><pub-id pub-id-type="pmid">21905149</pub-id><pub-id pub-id-type="pmcid">PMC3256278</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czub</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weingartl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>23</volume><fpage>2273</fpage>&#8211;<lpage>2279</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.033</pub-id><pub-id pub-id-type="pmid">15755610</pub-id><pub-id pub-id-type="pmcid">PMC7115540</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danilczyk</surname><given-names>U.</given-names></name><name name-style="western"><surname>Penninger</surname><given-names>J. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Angiotensin-converting enzyme II in the heart and the kidney.</article-title><source><italic toggle="yes">Circ. Res.</italic></source><volume>98</volume><fpage>463</fpage>&#8211;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000205761.22353.5f</pub-id><pub-id pub-id-type="pmid">16514079</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clercq</surname><given-names>E.</given-names></name><name name-style="western"><surname>De</surname></name></person-group> (<year>2016</year>). <article-title>Approved antiviral drugs over the past 50 years.</article-title><source><italic toggle="yes">Clin. Microbiol. Rev.</italic></source><volume>29</volume><fpage>695</fpage>&#8211;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00102-15.Address</pub-id><pub-id pub-id-type="pmid">27281742</pub-id><pub-id pub-id-type="pmcid">PMC4978613</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Wilde</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Jochmans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Van Nieuwkoop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.</article-title><source><italic toggle="yes">Antimicrob. Agents Chemother.</italic></source><volume>58</volume><fpage>4875</fpage>&#8211;<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.03011-3014</pub-id><pub-id pub-id-type="pmid">24841269</pub-id><pub-id pub-id-type="pmcid">PMC4136071</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>117</volume><fpage>6771</fpage>&#8211;<lpage>6776</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id><pub-id pub-id-type="pmid">32054787</pub-id><pub-id pub-id-type="pmcid">PMC7104368</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Horne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cameroni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>163</volume><fpage>70</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.01.016</pub-id><pub-id pub-id-type="pmid">30684561</pub-id><pub-id pub-id-type="pmcid">PMC7113761</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saturday</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>156</volume><fpage>64</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.06.006</pub-id><pub-id pub-id-type="pmid">29885377</pub-id><pub-id pub-id-type="pmcid">PMC7113689</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V. J.</given-names></name></person-group> (<year>2016</year>). <article-title>SARS and MERS: Recent insights into emerging coronaviruses.</article-title><source><italic toggle="yes">Nat. Rev. Microbiol.</italic></source><volume>14</volume><fpage>523</fpage>&#8211;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id><pub-id pub-id-type="pmcid">PMC7097822</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.</article-title><source><italic toggle="yes">PLoS Med.</italic></source><volume>3</volume>:<issue>e0030525</issue>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0030525</pub-id><pub-id pub-id-type="pmid">17194199</pub-id><pub-id pub-id-type="pmcid">PMC1716185</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>StJohn</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>A.</given-names></name><name name-style="western"><surname>Banach</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Sleeman</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>88</volume><fpage>11886</fpage>&#8211;<lpage>11898</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01528-1514</pub-id><pub-id pub-id-type="pmid">25100843</pub-id><pub-id pub-id-type="pmcid">PMC4178758</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Emerg. Microbes Infect.</italic></source><volume>7</volume>:<issue>60</issue><pub-id pub-id-type="doi">10.1038/s41426-018-0056-57</pub-id><pub-id pub-id-type="pmcid">PMC5884803</pub-id><pub-id pub-id-type="pmid">29618723</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity.</article-title><source><italic toggle="yes">RNA Biol.</italic></source><volume>8</volume><fpage>270</fpage>&#8211;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.4161/rna.8.2.15013</pub-id><pub-id pub-id-type="pmid">21593585</pub-id><pub-id pub-id-type="pmcid">PMC3127101</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dicaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Severe acute respiratory syndrome - related coronavirus is inhibited by interferon- a.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>189</volume><fpage>1164</fpage>&#8211;<lpage>1167</lpage>. <pub-id pub-id-type="doi">10.1086/382597</pub-id><pub-id pub-id-type="pmid">15031783</pub-id><pub-id pub-id-type="pmcid">PMC7109643</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>The clinical pathology of severe acute respiratory syndrome (SARS): a report from China.</article-title><source><italic toggle="yes">J. Pathol.</italic></source><volume>200</volume><fpage>282</fpage>&#8211;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1002/path.1440</pub-id><pub-id pub-id-type="pmid">12845623</pub-id><pub-id pub-id-type="pmcid">PMC7168017</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drake</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>J. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Mutation rates among RNA viruses.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>96</volume><fpage>13910</fpage>&#8211;<lpage>13913</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.96.24.13910</pub-id><pub-id pub-id-type="pmid">10570172</pub-id><pub-id pub-id-type="pmcid">PMC24164</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Panning</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated Coronavirus.</article-title><source><italic toggle="yes">J. Clin. Microbiol.</italic></source><volume>42</volume><fpage>2043</fpage>&#8211;<lpage>2047</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.42.5.2043-2047.2004</pub-id><pub-id pub-id-type="pmid">15131168</pub-id><pub-id pub-id-type="pmcid">PMC404639</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Middle East respiratory syndrome: current status and future prospects for vaccine development.</article-title><source><italic toggle="yes">Expert Opin. Biol. Ther.</italic></source><volume>15</volume><fpage>1647</fpage>&#8211;<lpage>1651</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.2015.1092518</pub-id><pub-id pub-id-type="pmid">26414077</pub-id><pub-id pub-id-type="pmcid">PMC4636333</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses?: implication for developing therapeutics and vaccines.</article-title><source><italic toggle="yes">PLoS One</italic></source><volume>8</volume>:<issue>e0081587</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0081587</pub-id><pub-id pub-id-type="pmid">24324708</pub-id><pub-id pub-id-type="pmcid">PMC3852489</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C. C. S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>A 219-mer CHO-Expressing Receptor-Binding Domain.</article-title><source><italic toggle="yes">Viral Immunol.</italic></source><volume>23</volume><fpage>211</fpage>&#8211;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2009.0090</pub-id><pub-id pub-id-type="pmid">20374001</pub-id><pub-id pub-id-type="pmcid">PMC2883479</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-.</article-title><source><italic toggle="yes">J. Immunol.</italic></source><volume>180</volume><fpage>948</fpage>&#8211;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.180.2.948</pub-id><pub-id pub-id-type="pmid">18178835</pub-id><pub-id pub-id-type="pmcid">PMC2603051</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>88</volume><fpage>7045</fpage>&#8211;<lpage>7053</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00433-14</pub-id><pub-id pub-id-type="pmid">24719424</pub-id><pub-id pub-id-type="pmcid">PMC4054355</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckerle</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Halpin</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Venter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing.</article-title><source><italic toggle="yes">PLoS Pathog.</italic></source><volume>6</volume>:<issue>e1000896</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000896</pub-id><pub-id pub-id-type="pmid">20463816</pub-id><pub-id pub-id-type="pmcid">PMC2865531</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckerle</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sperry</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name></person-group> (<year>2007</year>). <article-title>High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>81</volume><fpage>12135</fpage>&#8211;<lpage>12144</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01296-1297</pub-id><pub-id pub-id-type="pmid">17804504</pub-id><pub-id pub-id-type="pmcid">PMC2169014</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Excoffon</surname><given-names>K. J. D. A.</given-names></name><name name-style="western"><surname>Koerber</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Murtha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keshavjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaspar</surname><given-names>B. K.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Directed evolution of adeno-associated virus to an infectious respiratory virus.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>106</volume><fpage>3865</fpage>&#8211;<lpage>3870</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0813365106</pub-id><pub-id pub-id-type="pmid">19237554</pub-id><pub-id pub-id-type="pmcid">PMC2646629</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martellaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Callison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H.</given-names></name></person-group> (<year>2013a</year>). <article-title>Inhibition of novel &#946; coronavirus replication by a combination of interferon-&#945;2b and ribavirin.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>3</volume><fpage>1</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/srep01686</pub-id><pub-id pub-id-type="pmid">23594967</pub-id><pub-id pub-id-type="pmcid">PMC3629412</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D. P.</given-names></name><etal/></person-group> (<year>2013b</year>). <article-title>Treatment with interferon-&#945;2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>19</volume><fpage>1313</fpage>&#8211;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3362</pub-id><pub-id pub-id-type="pmid">24013700</pub-id><pub-id pub-id-type="pmcid">PMC4093902</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Subissi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Theresa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morais</surname><given-names>S. De</given-names></name><name name-style="western"><surname>Thi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>115</volume><fpage>E162</fpage>&#8211;<lpage>E171</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1718806115</pub-id><pub-id pub-id-type="pmid">29279395</pub-id><pub-id pub-id-type="pmcid">PMC5777078</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frieman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>SARS coronavirus and innate immunity.</article-title><source><italic toggle="yes">Virus Res.</italic></source><volume>133</volume><fpage>101</fpage>&#8211;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.015</pub-id><pub-id pub-id-type="pmid">17451827</pub-id><pub-id pub-id-type="pmcid">PMC2292640</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fry</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nahar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharmin</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gubareva</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce infl uenza illness duration and virus shedding in an urban setting in Bangladesh?: a randomised placebo-controlled trial.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>14</volume><fpage>109</fpage>&#8211;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70267-70266</pub-id><pub-id pub-id-type="pmid">24268590</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of middle east respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>87</volume><fpage>13134</fpage>&#8211;<lpage>13140</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02433-2413</pub-id><pub-id pub-id-type="pmid">24067982</pub-id><pub-id pub-id-type="pmcid">PMC3838252</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gierer</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Heurich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Springstein</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Karsten</surname><given-names>C. B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>211</volume><fpage>889</fpage>&#8211;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu407</pub-id><pub-id pub-id-type="pmid">25057042</pub-id><pub-id pub-id-type="pmcid">PMC7107327</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>DeBose-Boyd</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Protein sensors for membrane sterols.</article-title><source><italic toggle="yes">Cell</italic></source><volume>124</volume><fpage>35</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2005.12.022</pub-id><pub-id pub-id-type="pmid">16413480</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Ambrosino</surname><given-names>D. M.</given-names></name></person-group> (<year>2015</year>). <article-title>History of passive antibody administration for prevention and treatment of infectious diseases.</article-title><source><italic toggle="yes">Curr. Opin. HIV AIDS</italic></source><volume>10</volume><fpage>129</fpage>&#8211;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1097/COH.0000000000000154</pub-id><pub-id pub-id-type="pmid">25760933</pub-id><pub-id pub-id-type="pmcid">PMC4437582</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2012</year>). <article-title>A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>18</volume><fpage>1820</fpage>&#8211;<lpage>1826</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2972</pub-id><pub-id pub-id-type="pmid">23142821</pub-id><pub-id pub-id-type="pmcid">PMC3518599</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform.</article-title><source><italic toggle="yes">Commun. Biol.</italic></source><volume>1</volume>:<issue>179</issue><pub-id pub-id-type="doi">10.1038/s42003-018-0175-177</pub-id><pub-id pub-id-type="pmcid">PMC6206136</pub-id><pub-id pub-id-type="pmid">30393776</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Molecular pathology of emerging coronavirus infections.</article-title><source><italic toggle="yes">J. Pathol.</italic></source><volume>235</volume><fpage>185</fpage>&#8211;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1002/path.4454</pub-id><pub-id pub-id-type="pmid">25270030</pub-id><pub-id pub-id-type="pmcid">PMC4267971</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenough</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Babcock</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>W. D.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2005</year>). <article-title>Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>191</volume><fpage>507</fpage>&#8211;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1086/427242</pub-id><pub-id pub-id-type="pmid">15655773</pub-id><pub-id pub-id-type="pmcid">PMC7110081</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Immunology</italic></source><volume>145</volume><fpage>476</fpage>&#8211;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12462</pub-id><pub-id pub-id-type="pmid">25762305</pub-id><pub-id pub-id-type="pmcid">PMC4515128</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R. A. M.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>van Amerongen</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Pegylated interferon-&#945; protects type 1 pneumocytes against SARS coronavirus infection in macaques.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>10</volume><fpage>290</fpage>&#8211;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/nm1001</pub-id><pub-id pub-id-type="pmid">14981511</pub-id><pub-id pub-id-type="pmcid">PMC7095986</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>van den Brand</surname><given-names>J. M. A.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wohlsein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.</article-title><source><italic toggle="yes">Science</italic></source><volume>351</volume><fpage>77</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad1283</pub-id><pub-id pub-id-type="pmid">26678878</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansel</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Kropshofer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>George</surname><given-names>A. J. T.</given-names></name></person-group> (<year>2010</year>). <article-title>The safety and side effects of monoclonal antibodies.</article-title><source><italic toggle="yes">Nat. Rev. Drug Discov.</italic></source><volume>9</volume><fpage>325</fpage>&#8211;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3003</pub-id><pub-id pub-id-type="pmid">20305665</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hapfelmeier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>M. A. E.</given-names></name><name name-style="western"><surname>Slack</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kirundi</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Stoel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses.</article-title><source><italic toggle="yes">Science</italic></source><volume>328</volume><fpage>1705</fpage>&#8211;<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1126/science.1188454</pub-id><pub-id pub-id-type="pmid">20576892</pub-id><pub-id pub-id-type="pmcid">PMC3923373</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harcourt</surname><given-names>B. H.</given-names></name><name name-style="western"><surname>Jukneliene</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kanjanahaluethai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bechill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Severson</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>78</volume><fpage>13600</fpage>&#8211;<lpage>13612</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.78.24.13600</pub-id><pub-id pub-id-type="pmid">15564471</pub-id><pub-id pub-id-type="pmcid">PMC533933</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Dyall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Postnikova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kindrachuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R. F.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Interferon-&#946; and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays.</article-title><source><italic toggle="yes">J. Gen. Virol.</italic></source><volume>95</volume><fpage>571</fpage>&#8211;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.061911-61910</pub-id><pub-id pub-id-type="pmid">24323636</pub-id><pub-id pub-id-type="pmcid">PMC3929173</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashem</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Al-Amri</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Alhabbab</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Sohrab</surname><given-names>S. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A highly immunogenic, protective, and safe adenovirus-based vaccine expressing middle east respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>220</volume><fpage>1558</fpage>&#8211;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiz137</pub-id><pub-id pub-id-type="pmid">30911758</pub-id><pub-id pub-id-type="pmcid">PMC7107499</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holshue</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>DeBolt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lofy</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Wiesman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>First case of 2019 novel coronavirus in the United States.</article-title><source><italic toggle="yes">N. Engl. J. Med.</italic></source><volume>382</volume><fpage>929</fpage>&#8211;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2001191</pub-id><pub-id pub-id-type="pmid">32004427</pub-id><pub-id pub-id-type="pmcid">PMC7092802</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houser</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Gretebeck</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>213</volume><fpage>1557</fpage>&#8211;<lpage>1561</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw080</pub-id><pub-id pub-id-type="pmid">26941283</pub-id><pub-id pub-id-type="pmcid">PMC4837915</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsueh</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus.</article-title><source><italic toggle="yes">Clin. Microbiol. Infect.</italic></source><volume>10</volume><fpage>1062</fpage>&#8211;<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.01009.x</pub-id><pub-id pub-id-type="pmid">15606632</pub-id><pub-id pub-id-type="pmcid">PMC7129952</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>25</volume><fpage>6334</fpage>&#8211;<lpage>6340</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.017</pub-id><pub-id pub-id-type="pmid">17640780</pub-id><pub-id pub-id-type="pmcid">PMC7115497</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H. Z.</given-names></name></person-group> (<year>2008</year>). <article-title>Helicases as antiviral drug targets.</article-title><source><italic toggle="yes">Hong Kong Med. J.</italic></source><volume>14</volume><fpage>36</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">18708673</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huentelman</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Zubcevic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hern&#225;ndez Prada</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>M. K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Sructure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.</article-title><source><italic toggle="yes">Hypertension</italic></source><volume>44</volume><fpage>903</fpage>&#8211;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1161/01.HYP.0000146120.29648.36</pub-id><pub-id pub-id-type="pmid">15492138</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>I. E.</given-names></name><name name-style="western"><surname>Madani</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Ntoumi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health &#8212; The latest 2019 novel coronavirus outbreak in Wuhan.</article-title><source><italic toggle="yes">China Int. J. Infect. Dis.</italic></source><volume>91</volume><fpage>264</fpage>&#8211;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.009</pub-id><pub-id pub-id-type="pmid">31953166</pub-id><pub-id pub-id-type="pmcid">PMC7128332</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>88</volume><fpage>8597</fpage>&#8211;<lpage>8614</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00983-914</pub-id><pub-id pub-id-type="pmid">24850731</pub-id><pub-id pub-id-type="pmcid">PMC4135953</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagger</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burgomaster</surname><given-names>K. E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Protective efficacy of nucleic acid vaccines against transmission of zika virus during pregnancy in mice.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>220</volume><fpage>1577</fpage>&#8211;<lpage>1588</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiz338</pub-id><pub-id pub-id-type="pmid">31260518</pub-id><pub-id pub-id-type="pmcid">PMC6782106</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baoying</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>35</volume><fpage>10</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>K.-M. M. V.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.</article-title><source><italic toggle="yes">Sci. Transl. Med.</italic></source><volume>6</volume>:<issue>234ra59</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3008140</pub-id><pub-id pub-id-type="pmid">24778414</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Bagci</surname><given-names>U.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mollura</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.</article-title><source><italic toggle="yes">Virology</italic></source><volume>490</volume><fpage>49</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.01.004</pub-id><pub-id pub-id-type="pmid">26828465</pub-id><pub-id pub-id-type="pmcid">PMC4769911</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaemmerer</surname><given-names>W. F.</given-names></name></person-group> (<year>2018</year>). <article-title>How will the field of gene therapy survive its success?</article-title><source><italic toggle="yes">Bioeng. Transl. Med.</italic></source><volume>3</volume><fpage>166</fpage>&#8211;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1002/btm2.10090</pub-id><pub-id pub-id-type="pmid">30065971</pub-id><pub-id pub-id-type="pmcid">PMC6063870</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>Y. W.</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells <italic toggle="yes">in vitro</italic>.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>25</volume><fpage>729</fpage>&#8211;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.011</pub-id><pub-id pub-id-type="pmid">17049691</pub-id><pub-id pub-id-type="pmcid">PMC7115629</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandeel</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Bioinformatics analysis of the recent MERS-CoV with special reference to the virus-encoded Spike protein.</article-title><source><italic toggle="yes">Mol. Enzymol. Drug Targets</italic></source><volume>01</volume><fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.21767/2572-5475.10001</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapadia</surname><given-names>S. U.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</article-title><source><italic toggle="yes">Virology</italic></source><volume>340</volume><fpage>174</fpage>&#8211;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2005.06.016</pub-id><pub-id pub-id-type="pmid">16043204</pub-id><pub-id pub-id-type="pmcid">PMC7111745</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplitt</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Feigin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fitzsimons</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Mattis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#8217;s disease: an open label, phase I trial.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>369</volume><fpage>2097</fpage>&#8211;<lpage>2105</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60982-60989</pub-id><pub-id pub-id-type="pmid">17586305</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>D. S. Y.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>W. Y. Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?</article-title><source><italic toggle="yes">Am. J. Epidemiol.</italic></source><volume>159</volume><fpage>229</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwh056</pub-id><pub-id pub-id-type="pmid">14742282</pub-id><pub-id pub-id-type="pmcid">PMC7110237</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kay</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Manno</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Couto</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>McClelland</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.</article-title><source><italic toggle="yes">Nat. Genet.</italic></source><volume>24</volume><fpage>257</fpage>&#8211;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1038/73464</pub-id><pub-id pub-id-type="pmid">10700178</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al Rabiah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al Mobeireek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Al Mutairy</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Ribavirin and interferon-alpha2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.</article-title><source><italic toggle="yes">Antivir. Ther.</italic></source><volume>20</volume><fpage>87</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.3851/IMP2792</pub-id><pub-id pub-id-type="pmid">24831606</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al Rabiah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alismaili</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saleemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rehan-Khaliq</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Middle eastern respiratory syndrome corona virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.</article-title><source><italic toggle="yes">Ann. Saudi Med.</italic></source><volume>34</volume><fpage>396</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.5144/0256-4947.2014.396</pub-id><pub-id pub-id-type="pmid">25827696</pub-id><pub-id pub-id-type="pmcid">PMC6074560</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kenniston</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>AlHajri</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Farag</surname><given-names>E. A. B. A. B. A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Immunogenicity of an adenoviral-based Middle East Respiratory syndrome coronavirus vaccine in BALB/c mice.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>32</volume><fpage>5975</fpage>&#8211;<lpage>5982</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.058</pub-id><pub-id pub-id-type="pmid">25192975</pub-id><pub-id pub-id-type="pmcid">PMC7115510</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>U. J.</given-names></name><name name-style="western"><surname>Won</surname><given-names>E.-J.</given-names></name><name name-style="western"><surname>Kee</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.-C.</given-names></name></person-group> (<year>2016</year>). <article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome.</article-title><source><italic toggle="yes">Antivir. Ther.</italic></source><volume>21</volume><fpage>455</fpage>&#8211;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.3851/IMP3002</pub-id><pub-id pub-id-type="pmid">26492219</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirchdoerfer</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pallesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H. L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Pre-fusion structure of a human coronavirus spike protein.</article-title><source><italic toggle="yes">Nature</italic></source><volume>531</volume><fpage>118</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1038/nature17200</pub-id><pub-id pub-id-type="pmid">26935699</pub-id><pub-id pub-id-type="pmcid">PMC4860016</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Elzayat</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Elzayat</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>93</volume><fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01381-1318</pub-id><pub-id pub-id-type="pmcid">PMC6321919</pub-id><pub-id pub-id-type="pmid">30404801</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Seok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>Y. E.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience.</article-title><source><italic toggle="yes">Antivir. Ther.</italic></source><volume>23</volume><fpage>617</fpage>&#8211;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.3851/IMP3243</pub-id><pub-id pub-id-type="pmid">29923831</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobinger</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Figueredo</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sanmiguel</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>25</volume><fpage>5220</fpage>&#8211;<lpage>5231</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.065</pub-id><pub-id pub-id-type="pmid">17559989</pub-id><pub-id pub-id-type="pmcid">PMC7115643</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Shie</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Go</surname><given-names>Y. Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>141</volume><fpage>101</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.02.007</pub-id><pub-id pub-id-type="pmid">28216367</pub-id><pub-id pub-id-type="pmcid">PMC7113684</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden syrian hamsters.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>82</volume><fpage>7721</fpage>&#8211;<lpage>7724</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00304-308</pub-id><pub-id pub-id-type="pmid">18463152</pub-id><pub-id pub-id-type="pmcid">PMC2493341</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the middle east respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.</article-title><source><italic toggle="yes">PLoS One</italic></source><volume>9</volume>:<issue>e0112602</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge.</article-title><source><italic toggle="yes">EBioMedicine</italic></source><volume>2</volume><fpage>1438</fpage>&#8211;<lpage>1446</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmid">26629538</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>S. K. P.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>C. C. Y.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V. C. C.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Coronavirus HKU1 and other coronavirus infections in Hong Kong.</article-title><source><italic toggle="yes">J. Clin. Microbiol.</italic></source><volume>44</volume><fpage>2063</fpage>&#8211;<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.02614-2615</pub-id><pub-id pub-id-type="pmid">16757599</pub-id><pub-id pub-id-type="pmcid">PMC1489438</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauring</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Quasispecies theory and the behavior of RNA viruses.</article-title><source><italic toggle="yes">PLoS Pathog.</italic></source><volume>6</volume>:<issue>e1001005</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1001005</pub-id><pub-id pub-id-type="pmid">20661479</pub-id><pub-id pub-id-type="pmcid">PMC2908548</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laursen</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Friesen</surname><given-names>R. H. E.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jongeneelen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blokland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vermond</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.</article-title><source><italic toggle="yes">Science</italic></source><volume>362</volume><fpage>598</fpage>&#8211;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaq0620</pub-id><pub-id pub-id-type="pmid">30385580</pub-id><pub-id pub-id-type="pmcid">PMC6241527</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Giving the genes a shuffle: using natural variation to understand host genetic contributions to viral infections.</article-title><source><italic toggle="yes">Trends Genet.</italic></source><volume>34</volume><fpage>777</fpage>&#8211;<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2018.07.005</pub-id><pub-id pub-id-type="pmid">30131185</pub-id><pub-id pub-id-type="pmcid">PMC7114642</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure, function, and evolution of coronavirus spike proteins.</article-title><source><italic toggle="yes">Annu. Rev. Virol.</italic></source><volume>3</volume><fpage>237</fpage>&#8211;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-110615-142301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.</article-title><source><italic toggle="yes">Nature</italic></source><volume>426</volume><fpage>450</fpage>&#8211;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Bats are natural reservoirs of SARS-like coronaviruses.</article-title><source><italic toggle="yes">Science</italic></source><volume>310</volume><fpage>676</fpage>&#8211;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1126/science.1118391</pub-id><pub-id pub-id-type="pmid">16195424</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Zhijian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Grieger</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Ping-Jie</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Generation of novel aav variants by directed evolution for improved cftr delivery to human ciliated airway epithelium.</article-title><source><italic toggle="yes">Mol. Ther.</italic></source><volume>17</volume><fpage>2067</fpage>&#8211;<lpage>2077</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2009.155</pub-id><pub-id pub-id-type="pmid">19603002</pub-id><pub-id pub-id-type="pmcid">PMC2801879</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.</article-title><source><italic toggle="yes">Cell Res.</italic></source><volume>25</volume><fpage>1237</fpage>&#8211;<lpage>1249</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2015.113</pub-id><pub-id pub-id-type="pmid">26391698</pub-id><pub-id pub-id-type="pmcid">PMC4650419</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Human coronaviruses: a review of virus-host interactions.</article-title><source><italic toggle="yes">Diseases</italic></source><volume>4</volume><issue>26</issue>. <pub-id pub-id-type="doi">10.3390/diseases4030026</pub-id><pub-id pub-id-type="pmid">28933406</pub-id><pub-id pub-id-type="pmcid">PMC5456285</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limberis</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kobasa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>T. M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.</article-title><source><italic toggle="yes">Sci. Transl. Med.</italic></source><volume>5</volume>:<issue>187ra72</issue><pub-id pub-id-type="doi">10.1126/scitranslmed.3006729</pub-id><pub-id pub-id-type="pmcid">PMC4596530</pub-id><pub-id pub-id-type="pmid">23720583</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limberis</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Tretiakova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nambiar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Racine</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crosariol</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Adeno-associated virus serotype 9-expressed zmapp in mice confers protection against systemic and airway-acquired ebola virus infection.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>214</volume><fpage>1975</fpage>&#8211;<lpage>1979</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw460</pub-id><pub-id pub-id-type="pmid">27683818</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limberis</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pickles</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium <italic toggle="yes"><underline>in vitro</underline></italic>.</article-title><source><italic toggle="yes">Mol. Ther.</italic></source><volume>17</volume><fpage>294</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2008.261</pub-id><pub-id pub-id-type="pmid">19066597</pub-id><pub-id pub-id-type="pmcid">PMC2835069</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balazs</surname><given-names>A. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against hiv-1 11 medical and health sciences 1103 clinical sciences 11 medical and health sciences 1108 medical microbiology marit van Gils, m.j.vangils@amc.</article-title><source><italic toggle="yes">Retrovirology</italic></source><volume>15</volume><fpage>1</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1186/s12977-018-0449-447</pub-id><pub-id pub-id-type="pmid">30285769</pub-id><pub-id pub-id-type="pmcid">PMC6167872</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipkin</surname><given-names>W. I.</given-names></name><name name-style="western"><surname>Firth</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Viral surveillance and discovery.</article-title><source><italic toggle="yes">Curr. Opin. Virol.</italic></source><volume>3</volume><fpage>199</fpage>&#8211;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2013.03.010</pub-id><pub-id pub-id-type="pmid">23602435</pub-id><pub-id pub-id-type="pmcid">PMC4310698</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>29</volume><fpage>6606</fpage>&#8211;<lpage>6613</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.111</pub-id><pub-id pub-id-type="pmid">21762752</pub-id><pub-id pub-id-type="pmcid">PMC3165014</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arvey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sudhamsu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shrivastava-Ranjan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hotard</surname><given-names>A. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>7</volume><fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/srep43395</pub-id><pub-id pub-id-type="pmid">28262699</pub-id><pub-id pub-id-type="pmcid">PMC5338263</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Yoshikawa-Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Wyde</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>26</volume><fpage>797</fpage>&#8211;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.092</pub-id><pub-id pub-id-type="pmid">18191004</pub-id><pub-id pub-id-type="pmcid">PMC2267761</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loustaud-Ratti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Debette-Gratien</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sautereau</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Ribavirin: Past, present and future.</article-title><source><italic toggle="yes">World J. Hepatol.</italic></source><volume>8</volume><fpage>123</fpage>&#8211;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.4254/wjh.v8.i2.123</pub-id><pub-id pub-id-type="pmid">26807208</pub-id><pub-id pub-id-type="pmcid">PMC4716528</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loutfy</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Blatt</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Siminovitch</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lho</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study.</article-title><source><italic toggle="yes">JAMA</italic></source><volume>290</volume><fpage>3222</fpage>&#8211;<lpage>3228</lpage>. <pub-id pub-id-type="doi">10.1001/jama.290.24.3222</pub-id><pub-id pub-id-type="pmid">14693875</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>5</volume>:<issue>3067</issue>. <pub-id pub-id-type="doi">10.1038/ncomms4067</pub-id><pub-id pub-id-type="pmid">24473083</pub-id><pub-id pub-id-type="pmcid">PMC7091805</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>6736</volume><fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-30258</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Discovery of novel bat coronaviruses in south china that use the same receptor as middle east respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume>:<issue>e00116-18</issue><pub-id pub-id-type="doi">10.1128/JVI.00116-118</pub-id><pub-id pub-id-type="pmcid">PMC6002729</pub-id><pub-id pub-id-type="pmid">29669833</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T. K.</given-names></name><etal/></person-group> (<year>2014a</year>). <article-title>Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>32</volume><fpage>2100</fpage>&#8211;<lpage>2108</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.004</pub-id><pub-id pub-id-type="pmid">24560617</pub-id><pub-id pub-id-type="pmcid">PMC4194189</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T. K.</given-names></name><etal/></person-group> (<year>2014b</year>). <article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments&#8212;The importance of immunofocusing in subunit vaccine design.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>32</volume><fpage>6170</fpage>&#8211;<lpage>6176</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.086</pub-id><pub-id pub-id-type="pmid">25240756</pub-id><pub-id pub-id-type="pmcid">PMC4194190</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackenzie</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Jeggo</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Reservoirs and vectors of emerging viruses.</article-title><source><italic toggle="yes">Curr. Opin. Virol.</italic></source><volume>3</volume><fpage>170</fpage>&#8211;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2013.02.002</pub-id><pub-id pub-id-type="pmid">23491947</pub-id><pub-id pub-id-type="pmcid">PMC7102734</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khaw</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W. S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>211</volume><fpage>80</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu396</pub-id><pub-id pub-id-type="pmid">25030060</pub-id><pub-id pub-id-type="pmcid">PMC4264590</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malczyk</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pr&#252;fer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scheuplein</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Hutzler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kreuz</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>89</volume><fpage>11654</fpage>&#8211;<lpage>11667</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01815-15</pub-id><pub-id pub-id-type="pmid">26355094</pub-id><pub-id pub-id-type="pmcid">PMC4645655</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Louder</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>L. S. A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>B. D.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>26</volume><fpage>6338</fpage>&#8211;<lpage>6343</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmid">18824060</pub-id><pub-id pub-id-type="pmcid">PMC2612543</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>M.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukushi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Middle East Respiratory syndrome coronavirus spike protein is not activated directly by cellular furin during viral entry into target cells.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume>:<issue>e00683-18</issue><pub-id pub-id-type="doi">10.1128/JVI.00683-618</pub-id><pub-id pub-id-type="pmcid">PMC6146822</pub-id><pub-id pub-id-type="pmid">30021905</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matteucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giampietro</surname><given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.</article-title><source><italic toggle="yes">Curr. Med. Chem.</italic></source><volume>4</volume><fpage>80</fpage>&#8211;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.2174/9781681082493116090005</pub-id><pub-id pub-id-type="pmid">19689275</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntosh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kapikian</surname><given-names>A. Z.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R. M.</given-names></name></person-group> (<year>1970</year>). <article-title>Seroepidemiologic studies of coronavirus infection in adults and children.</article-title><source><italic toggle="yes">Am. J. Epidemiol.</italic></source><volume>91</volume><fpage>585</fpage>&#8211;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a121171</pub-id><pub-id pub-id-type="pmid">4315625</pub-id><pub-id pub-id-type="pmcid">PMC7109868</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis.</article-title><source><italic toggle="yes">mSphere</italic></source><volume>2</volume><fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1128/msphere.00346-317</pub-id><pub-id pub-id-type="pmcid">PMC5687918</pub-id><pub-id pub-id-type="pmid">29152578</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Combination attenuation offers strategy for live attenuated coronavirus vaccines.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume><fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00710-718</pub-id><pub-id pub-id-type="pmcid">PMC6096805</pub-id><pub-id pub-id-type="pmid">29976657</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Debbink</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>21</volume><fpage>1508</fpage>&#8211;<lpage>1513</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3985</pub-id><pub-id pub-id-type="pmid">26552008</pub-id><pub-id pub-id-type="pmcid">PMC4797993</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Josset</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Scobey</surname><given-names>T.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2&#8217;-o-methyltransferase activity.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>88</volume><fpage>4251</fpage>&#8211;<lpage>4264</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.03571-3513</pub-id><pub-id pub-id-type="pmid">24478444</pub-id><pub-id pub-id-type="pmcid">PMC3993736</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Debbink</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>SARS-like WIV1-CoV poised for human emergence.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>113</volume><fpage>3048</fpage>&#8211;<lpage>3053</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1517719113</pub-id><pub-id pub-id-type="pmid">26976607</pub-id><pub-id pub-id-type="pmcid">PMC4801244</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>111</volume><fpage>15214</fpage>&#8211;<lpage>15219</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1407087111</pub-id><pub-id pub-id-type="pmid">25288733</pub-id><pub-id pub-id-type="pmcid">PMC4210292</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis.</article-title><source><italic toggle="yes">Virus Res.</italic></source><volume>202</volume><fpage>120</fpage>&#8211;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.11.021</pub-id><pub-id pub-id-type="pmid">25445340</pub-id><pub-id pub-id-type="pmcid">PMC4465284</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells.</article-title><source><italic toggle="yes">Virology</italic></source><volume>517</volume><fpage>3</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2017.12.015</pub-id><pub-id pub-id-type="pmid">29275820</pub-id><pub-id pub-id-type="pmcid">PMC7112017</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China.</article-title><source><italic toggle="yes">Science</italic></source><volume>303</volume><fpage>1666</fpage>&#8211;<lpage>1669</lpage>. <pub-id pub-id-type="doi">10.1126/science.1092002</pub-id><pub-id pub-id-type="pmid">14752165</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>A review of treatment modalities for Middle East Respiratory Syndrome.</article-title><source><italic toggle="yes">J. Antimicrob. Chemother.</italic></source><volume>71</volume><fpage>3340</fpage>&#8211;<lpage>3350</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkw338</pub-id><pub-id pub-id-type="pmid">27585965</pub-id><pub-id pub-id-type="pmcid">PMC7109760</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Paolino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>19</volume><fpage>1013</fpage>&#8211;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(19)30266-X</pub-id><pub-id pub-id-type="pmid">31351922</pub-id><pub-id pub-id-type="pmcid">PMC7185789</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momattin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z. A.</given-names></name><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Therapeutic Options for Middle East respiratory syndrome coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.</article-title><source><italic toggle="yes">Int. J. Infect. Dis.</italic></source><volume>17</volume><fpage>e792</fpage>&#8211;<lpage>e798</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.07.002</pub-id><pub-id pub-id-type="pmid">23993766</pub-id><pub-id pub-id-type="pmcid">PMC7110699</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mubarak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alturaiki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hemida</surname><given-names>M. G.</given-names></name></person-group> (<year>2019</year>). <article-title>Middle east respiratory syndrome coronavirus (mers-cov): infection, immunological response, and vaccine development.</article-title><source><italic toggle="yes">J. Immunol. Res.</italic></source><volume>2019</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2019/6491738</pub-id><pub-id pub-id-type="pmid">31089478</pub-id><pub-id pub-id-type="pmcid">PMC6476043</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munster</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.</article-title><source><italic toggle="yes">NPJ Vaccines</italic></source><volume>2</volume><fpage>1</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41541-017-0029-21</pub-id><pub-id pub-id-type="pmid">29263883</pub-id><pub-id pub-id-type="pmcid">PMC5643297</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Perron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Eckstrand</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.</article-title><source><italic toggle="yes">Vet. Microbiol.</italic></source><volume>219</volume><fpage>226</fpage>&#8211;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2018.04.026</pub-id><pub-id pub-id-type="pmid">29778200</pub-id><pub-id pub-id-type="pmcid">PMC7117434</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flingai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>D. O.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.</article-title><source><italic toggle="yes">Sci. Transl. Med.</italic></source><volume>7</volume>:<issue>301ra132</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac7462</pub-id><pub-id pub-id-type="pmid">26290414</pub-id><pub-id pub-id-type="pmcid">PMC4573558</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naso</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Tomkowicz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Strohl</surname><given-names>W. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Adeno-associated virus (AAV) as a vector for gene therapy.</article-title><source><italic toggle="yes">BioDrugs</italic></source><volume>31</volume><fpage>317</fpage>&#8211;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1007/s40259-017-0234-235</pub-id><pub-id pub-id-type="pmid">28669112</pub-id><pub-id pub-id-type="pmcid">PMC5548848</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Kroeker</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Bestwick</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Iversen</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Inhibition and escape of SARS-CoV treated with antisense morpholino oligomers.</article-title><source><italic toggle="yes">Adv. Exp. Med. Biol.</italic></source><volume>581</volume><fpage>567</fpage>&#8211;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-33012-9_103</pub-id><pub-id pub-id-type="pmid">17037599</pub-id><pub-id pub-id-type="pmcid">PMC7123819</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salvetti</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>AAV vectors vaccines against infectious diseases.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>5</volume>:<issue>5</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00005</pub-id><pub-id pub-id-type="pmid">24478774</pub-id><pub-id pub-id-type="pmcid">PMC3896988</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyon</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T. K. T. K.</given-names></name><name name-style="western"><surname>Seid</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naceanceno</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>36</volume><fpage>1853</fpage>&#8211;<lpage>1862</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.065</pub-id><pub-id pub-id-type="pmid">29496347</pub-id><pub-id pub-id-type="pmcid">PMC5860679</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Bertoletti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Understanding the T cell immune response in SARS coronavirus infection.</article-title><source><italic toggle="yes">Emerg. Microbes Infect.</italic></source><volume>1</volume>:<issue>e23</issue>. <pub-id pub-id-type="doi">10.1038/emi.2012.26</pub-id><pub-id pub-id-type="pmid">26038429</pub-id><pub-id pub-id-type="pmcid">PMC3636424</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olinger</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Pettitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Working</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bohorov</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bratcher</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>109</volume><fpage>18030</fpage>&#8211;<lpage>18035</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1213709109</pub-id><pub-id pub-id-type="pmid">23071322</pub-id><pub-id pub-id-type="pmcid">PMC3497800</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omrani</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Baig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bahloul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdul-Matin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alaidaroos</surname><given-names>A. Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>14</volume><fpage>1090</fpage>&#8211;<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70920-X</pub-id><pub-id pub-id-type="pmid">25278221</pub-id><pub-id pub-id-type="pmcid">PMC7106357</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>H. A. O.</given-names></name><name name-style="western"><surname>Broxmeyer</surname><given-names>H. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Review Article Implications of DPP4 modi fi cation of proteins that regulate stem / progenitor and more mature cell types.</article-title><source><italic toggle="yes">Blood</italic></source><volume>122</volume><fpage>161</fpage>&#8211;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-02-487470.X.O</pub-id><pub-id pub-id-type="pmcid">PMC3709652</pub-id><pub-id pub-id-type="pmid">23637126</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirchdoerfer</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>114</volume><fpage>E7348</fpage>&#8211;<lpage>E7357</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id><pub-id pub-id-type="pmid">28807998</pub-id><pub-id pub-id-type="pmcid">PMC5584442</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascal</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Mujica</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Kamat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Badithe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fairhurst</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>112</volume><fpage>8738</fpage>&#8211;<lpage>8743</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1510830112</pub-id><pub-id pub-id-type="pmid">26124093</pub-id><pub-id pub-id-type="pmcid">PMC4507189</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payne</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Iblan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alqasrawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haddadin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nsour</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Persistence of antibodies against Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Emerg. Infect. Dis.</italic></source><volume>22</volume><fpage>1824</fpage>&#8211;<lpage>1826</lpage>.<pub-id pub-id-type="pmid">27332149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2210.160706</pub-id><pub-id pub-id-type="pmcid">PMC5038413</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peck</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Burch</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Coronavirus host range expansion and middle east respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives.</article-title><source><italic toggle="yes">Annu. Rev. Virol.</italic></source><volume>2</volume><fpage>95</fpage>&#8211;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-100114-155029</pub-id><pub-id pub-id-type="pmid">26958908</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Perron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bannasch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>E.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liepnieks</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis.</article-title><source><italic toggle="yes">J. Feline Med. Surg.</italic></source><volume>21</volume><fpage>271</fpage>&#8211;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1177/1098612X19825701</pub-id><pub-id pub-id-type="pmid">30755068</pub-id><pub-id pub-id-type="pmcid">PMC6435921</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>J. S. M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V. C. C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. S. H.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I. F. N.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L. L. M.</given-names></name><etal/></person-group> (<year>2003a</year>). <article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>361</volume><fpage>1767</fpage>&#8211;<lpage>1772</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-13415</pub-id><pub-id pub-id-type="pmid">12781535</pub-id><pub-id pub-id-type="pmcid">PMC7112410</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>J. S. M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L. L. M.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yam</surname><given-names>L. Y. C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2003b</year>). <article-title>Coronavirus as a possible cause of severe acute respiratory syndrome.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>361</volume><fpage>1319</fpage>&#8211;<lpage>1325</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13077-13072</pub-id><pub-id pub-id-type="pmid">12711465</pub-id><pub-id pub-id-type="pmcid">PMC7112372</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Netland</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Coronaviruses post-SARS: update on replication and pathogenesis.</article-title><source><italic toggle="yes">Nat. Rev. Microbiol.</italic></source><volume>7</volume><fpage>439</fpage>&#8211;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2147</pub-id><pub-id pub-id-type="pmid">19430490</pub-id><pub-id pub-id-type="pmcid">PMC2830095</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vijay</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Middle East respiratory syndrome vaccines.</article-title><source><italic toggle="yes">Int. J. Infect. Dis.</italic></source><volume>47</volume><fpage>23</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2016.04.008</pub-id><pub-id pub-id-type="pmid">27062985</pub-id><pub-id pub-id-type="pmcid">PMC4969153</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>SARS coronavirus infections of the lower respiratory tract and their prevention.</article-title><source><italic toggle="yes">Microbiol. Respir. Syst. Infect.</italic></source><volume>2016</volume><fpage>45</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-804543-5.00003-8</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Correlates of protection induced by vaccination.</article-title><source><italic toggle="yes">Clin. Vaccine Immunol.</italic></source><volume>17</volume><fpage>1055</fpage>&#8211;<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00131-110</pub-id><pub-id pub-id-type="pmid">20463105</pub-id><pub-id pub-id-type="pmcid">PMC2897268</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Biragyn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Broder</surname><given-names>C. C.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.</article-title><source><italic toggle="yes">Expert Opin. Biol. Ther.</italic></source><volume>9</volume><fpage>355</fpage>&#8211;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1517/14712590902763755</pub-id><pub-id pub-id-type="pmid">19216624</pub-id><pub-id pub-id-type="pmcid">PMC2705284</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyrc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Berkhout</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jebbink</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Dijkman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.</article-title><source><italic toggle="yes">Antimicrob. Agents Chemother.</italic></source><volume>50</volume><fpage>2000</fpage>&#8211;<lpage>2008</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01598-1595</pub-id><pub-id pub-id-type="pmid">16723558</pub-id><pub-id pub-id-type="pmcid">PMC1479111</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>132</volume><fpage>141</fpage>&#8211;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.06.003</pub-id><pub-id pub-id-type="pmid">27312105</pub-id><pub-id pub-id-type="pmcid">PMC5109928</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Audet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pillet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Successful treatment of ebola virus - infected cynomolgus macaques with monoclonal antibodies.</article-title><source><italic toggle="yes">Sci. Transl. Med.</italic></source><volume>4</volume><fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3003876</pub-id><pub-id pub-id-type="pmid">22700957</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>D. H. W.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Dijkman</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.</article-title><source><italic toggle="yes">Nature</italic></source><volume>495</volume><fpage>251</fpage>&#8211;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="pmid">23486063</pub-id><pub-id pub-id-type="pmcid">PMC7095326</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N. M. A.</given-names></name><name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>D.</given-names></name><name name-style="western"><surname>van Dieren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Widagdo</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection.</article-title><source><italic toggle="yes">Sci. Adv.</italic></source><volume>4</volume><fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aas9667</pub-id><pub-id pub-id-type="pmid">30101189</pub-id><pub-id pub-id-type="pmcid">PMC6082650</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A. D. M. E.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R. A. M.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name></person-group> (<year>2014</year>). <article-title>MERS: emergence of a novel human coronavirus.</article-title><source><italic toggle="yes">Curr. Opin. Virol.</italic></source><volume>5</volume><fpage>58</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.01.010</pub-id><pub-id pub-id-type="pmid">24584035</pub-id><pub-id pub-id-type="pmcid">PMC4028407</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reggiori</surname><given-names>F.</given-names></name><name name-style="western"><surname>Monastyrska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Verheije</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Cal&#236;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ulasli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Coronaviruses hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication.</article-title><source><italic toggle="yes">Cell Host Microbe</italic></source><volume>7</volume><fpage>500</fpage>&#8211;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2010.05.013</pub-id><pub-id pub-id-type="pmid">20542253</pub-id><pub-id pub-id-type="pmcid">PMC7103375</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>X. N.</given-names></name><name name-style="western"><surname>Alazard-Dany</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barateau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cimarelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Volchkov</surname><given-names>V. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Identification of a new ribonucleoside inhibitor of ebola virus replication.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>7</volume><fpage>6233</fpage>&#8211;<lpage>6240</lpage>. <pub-id pub-id-type="doi">10.3390/v7122934</pub-id><pub-id pub-id-type="pmid">26633464</pub-id><pub-id pub-id-type="pmcid">PMC4690858</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaee</surname><given-names>F.</given-names></name><name name-style="western"><surname>Linfield</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Harford</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Piedimonte</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Ongoing developments in RSV prophylaxis?: a clinician&#8217;s analysis.</article-title><source><italic toggle="yes">Curr. Opin. Virol.</italic></source><volume>112781</volume><fpage>70</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.015</pub-id><pub-id pub-id-type="pmid">28500974</pub-id><pub-id pub-id-type="pmcid">PMC5541395</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richner</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Modified mRNA vaccines protect against zika virus infection.</article-title><source><italic toggle="yes">Cell</italic></source><volume>168</volume><fpage>1114.e10</fpage>&#8211;<lpage>1125.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.02.017</pub-id><pub-id pub-id-type="pmid">28222903</pub-id><pub-id pub-id-type="pmcid">PMC5388441</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>G.</given-names></name><name name-style="western"><surname>Knott</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Immunogenicity and protective efficacy in mice and hamsters of a &#946;-propiolactone inactivated whole virus SARS-CoV vaccine.</article-title><source><italic toggle="yes">Viral Immunol.</italic></source><volume>23</volume><fpage>509</fpage>&#8211;<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2010.0028</pub-id><pub-id pub-id-type="pmid">20883165</pub-id><pub-id pub-id-type="pmcid">PMC2967819</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rockx</surname><given-names>B.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>82</volume><fpage>3220</fpage>&#8211;<lpage>3235</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02377-2377</pub-id><pub-id pub-id-type="pmid">18199635</pub-id><pub-id pub-id-type="pmcid">PMC2268459</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schunk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sothmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bretzel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Froeschl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wallrauch</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany.</article-title><source><italic toggle="yes">N. Engl. J. Med.</italic></source><volume>382</volume><fpage>970</fpage>&#8211;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2001468</pub-id><pub-id pub-id-type="pmid">32003551</pub-id><pub-id pub-id-type="pmcid">PMC7120970</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindewolf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name></person-group> (<year>2019</year>). <article-title>Middle east respiratory syndrome vaccine candidates: cautious optimism.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>11</volume>:<issue>74</issue>. <pub-id pub-id-type="doi">10.3390/v11010074</pub-id><pub-id pub-id-type="pmid">30658390</pub-id><pub-id pub-id-type="pmcid">PMC6356267</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>See</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>C. P. Y.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zitzow</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.</article-title><source><italic toggle="yes">J. Gen. Virol.</italic></source><volume>89</volume><fpage>2136</fpage>&#8211;<lpage>2146</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.2008/001891-1890</pub-id><pub-id pub-id-type="pmid">18753223</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>See</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Zakhartchouk</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>C. P. Y.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</article-title><source><italic toggle="yes">J. Gen. Virol.</italic></source><volume>87</volume><fpage>641</fpage>&#8211;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.81579-81570</pub-id><pub-id pub-id-type="pmid">16476986</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seong</surname><given-names>B. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Chaperna-mediated assembly of ferritin-based middle east respiratory syndrome-coronavirus nanoparticles.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>9</volume>:<issue>1093</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmid">29868035</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalhoub</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farahat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al-Jiffri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simhairi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shamma</surname><given-names>O.</given-names></name><name name-style="western"><surname>Siddiqi</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>IFN-&#945;2a or IFN-&#946;1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.</article-title><source><italic toggle="yes">J. Antimicrob. Chemother.</italic></source><volume>70</volume><fpage>2129</fpage>&#8211;<lpage>2132</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkv085</pub-id><pub-id pub-id-type="pmid">25900158</pub-id><pub-id pub-id-type="pmcid">PMC7202429</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharif-Yakan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kanj</surname><given-names>S. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Emergence of MERS-CoV in the middle east: origins, transmission, treatment, and perspectives.</article-title><source><italic toggle="yes">PLoS Pathog.</italic></source><volume>10</volume>:<issue>e1004457</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004457</pub-id><pub-id pub-id-type="pmid">25474536</pub-id><pub-id pub-id-type="pmcid">PMC4256428</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Case</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.</article-title><source><italic toggle="yes">Sci. Transl. Med.</italic></source><volume>9</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id><pub-id pub-id-type="pmid">28659436</pub-id><pub-id pub-id-type="pmcid">PMC5567817</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Won</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>11</volume>:<issue>222</issue><pub-id pub-id-type="doi">10.1038/s41467-019-13940-13946</pub-id><pub-id pub-id-type="pmcid">PMC6954302</pub-id><pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>I.</given-names></name><name name-style="western"><surname>Joh</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Immune responses to middle east respiratory syndrome coronavirus during the acute and convalescent phases of human infection.</article-title><source><italic toggle="yes">Clin. Infect. Dis.</italic></source><volume>68</volume><fpage>984</fpage>&#8211;<lpage>992</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy595</pub-id><pub-id pub-id-type="pmid">30060038</pub-id><pub-id pub-id-type="pmcid">PMC7108191</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gosalia</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Rennekamp</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>). <article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>102</volume><fpage>11876</fpage>&#8211;<lpage>11881</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0505577102</pub-id><pub-id pub-id-type="pmid">16081529</pub-id><pub-id pub-id-type="pmcid">PMC1188015</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>H.</given-names></name><name name-style="western"><surname>Surdel</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.</article-title><source><italic toggle="yes">PLoS Pathog.</italic></source><volume>9</volume>:<issue>e1003565</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003565</pub-id><pub-id pub-id-type="pmid">23966862</pub-id><pub-id pub-id-type="pmcid">PMC3744431</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snijder</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Onderwater</surname><given-names>J. J. M.</given-names></name><name name-style="western"><surname>van der Meulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koerten</surname><given-names>H. K.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>80</volume><fpage>5927</fpage>&#8211;<lpage>5940</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02501-2505</pub-id><pub-id pub-id-type="pmid">16731931</pub-id><pub-id pub-id-type="pmcid">PMC1472606</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Provacia</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>87</volume><fpage>11950</fpage>&#8211;<lpage>11954</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01672-1613</pub-id><pub-id pub-id-type="pmid">23986586</pub-id><pub-id pub-id-type="pmcid">PMC3807317</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spruth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hitter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gerencer</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>24</volume><fpage>652</fpage>&#8211;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.055</pub-id><pub-id pub-id-type="pmid">16214268</pub-id><pub-id pub-id-type="pmcid">PMC7115667</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>SARS vaccine protective in mice [2].</article-title><source><italic toggle="yes">Emerg. Infect. Dis.</italic></source><volume>11</volume><fpage>1312</fpage>&#8211;<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.3201/eid1108.041003</pub-id><pub-id pub-id-type="pmid">16110580</pub-id><pub-id pub-id-type="pmcid">PMC3320494</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stertz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reichelt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spiegel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Sobrido</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The intracellular sites of early replication and budding of SARS-coronavirus.</article-title><source><italic toggle="yes">Virology</italic></source><volume>361</volume><fpage>304</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2006.11.027</pub-id><pub-id pub-id-type="pmid">17210170</pub-id><pub-id pub-id-type="pmcid">PMC7103305</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strobel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zuckschwerdt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eytner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rechtsteiner</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Standardized, Scalable, and Timely Flexible Adeno-Associated Virus Vector Production Using Frozen High-Density HEK-293 Cell Stocks and CELLdiscs.</article-title><source><italic toggle="yes">Hum. Gene Ther. Methods</italic></source><volume>30</volume><fpage>23</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1089/hgtb.2018.228</pub-id><pub-id pub-id-type="pmid">30693792</pub-id><pub-id pub-id-type="pmcid">PMC6388714</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>101</volume><fpage>2536</fpage>&#8211;<lpage>2541</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0307140101</pub-id><pub-id pub-id-type="pmid">14983044</pub-id><pub-id pub-id-type="pmcid">PMC356985</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>J. J. Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P. K. S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak.</article-title><source><italic toggle="yes">Thorax</italic></source><volume>59</volume><fpage>414</fpage>&#8211;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2003.014076</pub-id><pub-id pub-id-type="pmid">15115870</pub-id><pub-id pub-id-type="pmcid">PMC1746995</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>91</volume>:<issue>e01651-16</issue><pub-id pub-id-type="doi">10.1128/JVI.01651-1616</pub-id><pub-id pub-id-type="pmcid">PMC5165220</pub-id><pub-id pub-id-type="pmid">27795425</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.</article-title><source><italic toggle="yes">Virology</italic></source><volume>499</volume><fpage>375</fpage>&#8211;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>E. L. C.</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.</article-title><source><italic toggle="yes">Emerg. Infect. Dis.</italic></source><volume>10</volume><fpage>581</fpage>&#8211;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.3201/eid1004.030458</pub-id><pub-id pub-id-type="pmid">15200845</pub-id><pub-id pub-id-type="pmcid">PMC3323075</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.</article-title><source><italic toggle="yes">J. Immunol.</italic></source><volume>186</volume><fpage>7264</fpage>&#8211;<lpage>7268</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0903490</pub-id><pub-id pub-id-type="pmid">21576510</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C. K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Optimization of antigen dose for a receptor- binding domain-based subunit vaccine against MERS coronavirus.</article-title><source><italic toggle="yes">Hum. Vaccines Immunother.</italic></source><volume>11</volume><fpage>1244</fpage>&#8211;<lpage>1250</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmid">25874632</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X. C.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stanhope</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>E. C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>111</volume><fpage>E2018</fpage>&#8211;<lpage>E2026</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1402074111</pub-id><pub-id pub-id-type="pmid">24778221</pub-id><pub-id pub-id-type="pmcid">PMC4024880</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ter Meulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A. B. H.</given-names></name><name name-style="western"><surname>Van Den Brink</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Weverling</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>B. E. E.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>363</volume><fpage>2139</fpage>&#8211;<lpage>2141</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16506-16509</pub-id><pub-id pub-id-type="pmid">15220038</pub-id><pub-id pub-id-type="pmcid">PMC7112500</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ter Meulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Den Brink</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L. L. M.</given-names></name><name name-style="western"><surname>Marissen</surname><given-names>W. E.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>C. S. W.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.</article-title><source><italic toggle="yes">PLoS Med.</italic></source><volume>3</volume>:<issue>e237</issue>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0030237</pub-id><pub-id pub-id-type="pmid">16796401</pub-id><pub-id pub-id-type="pmcid">PMC1483912</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <source><italic toggle="yes">Structural Insights into Coronavirus Entry</italic></source>, <edition>1st Edn</edition><publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.aivir.2019.08.002</pub-id><pub-id pub-id-type="pmcid">PMC7112261</pub-id><pub-id pub-id-type="pmid">31522710</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traggiai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gismondo</surname><given-names>M. R.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>10</volume><fpage>871</fpage>&#8211;<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1038/nm1080</pub-id><pub-id pub-id-type="pmid">15247913</pub-id><pub-id pub-id-type="pmcid">PMC7095806</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tse</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Klinc</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Madigan</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Castellanos Rivera</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Havlik</surname><given-names>L. P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>114</volume><fpage>E4812</fpage>&#8211;<lpage>E4821</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1704766114</pub-id><pub-id pub-id-type="pmid">28559317</pub-id><pub-id pub-id-type="pmcid">PMC5474820</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tse</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Moller-Tank</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asokan</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Strategies to circumvent humoral immunity to adeno-associated viral vectors.</article-title><source><italic toggle="yes">Expert Opin. Biol. Ther.</italic></source><volume>15</volume><fpage>845</fpage>&#8211;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.2015.1035645</pub-id><pub-id pub-id-type="pmid">25985812</pub-id><pub-id pub-id-type="pmcid">PMC4689135</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Developments in viral vector-based vaccines.</article-title><source><italic toggle="yes">Vaccines</italic></source><volume>2</volume><fpage>624</fpage>&#8211;<lpage>641</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urakova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuznetsova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Crossman</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Sokratian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Kolykhalov</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>&#946;-D- N 4 -hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume><fpage>1</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01965-1917</pub-id><pub-id pub-id-type="pmcid">PMC5774879</pub-id><pub-id pub-id-type="pmid">29167335</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Brink</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>ter Meulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jongeneelen</surname><given-names>M. A. C.</given-names></name><name name-style="western"><surname>Thijsse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Throsby</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>79</volume><fpage>1635</fpage>&#8211;<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.79.3.1635-1644.2005</pub-id><pub-id pub-id-type="pmid">15650189</pub-id><pub-id pub-id-type="pmcid">PMC544131</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>143</volume><fpage>30</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.025</pub-id><pub-id pub-id-type="pmid">28389142</pub-id><pub-id pub-id-type="pmcid">PMC6957253</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jany</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shams-Eldin</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Protective efficacy of recombinant modified vaccinia virus ankara delivering middle east respiratory syndrome coronavirus spike glycoprotein.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>89</volume><fpage>8651</fpage>&#8211;<lpage>8656</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00614-615</pub-id><pub-id pub-id-type="pmid">26018172</pub-id><pub-id pub-id-type="pmcid">PMC4524222</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quispe</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019a</year>). <article-title>Unexpected receptor functional mimicry elucidates activation of coronavirus fusion.</article-title><source><italic toggle="yes">Cell</italic></source><volume>176</volume><fpage>1026.e15</fpage>&#8211;<lpage>1039.e15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.028</pub-id><pub-id pub-id-type="pmid">30712865</pub-id><pub-id pub-id-type="pmcid">PMC6751136</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2019b</year>). <article-title>Activation of coronavirus fusion unexpected receptor functional mimicry elucidates activation of coronavirus fusion.</article-title><source><italic toggle="yes">Cell</italic></source><volume>176</volume><fpage>1026</fpage>&#8211;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">30712865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.12.028</pub-id><pub-id pub-id-type="pmcid">PMC6751136</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017a</year>). <article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>140</volume><fpage>55</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017b</year>). <article-title>MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.</article-title><source><italic toggle="yes">Oncotarget</italic></source><volume>8</volume><fpage>12686</fpage>&#8211;<lpage>12694</lpage>.<pub-id pub-id-type="pmid">27050368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.8475</pub-id><pub-id pub-id-type="pmcid">PMC5355045</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.</article-title><source><italic toggle="yes">Hum. Vaccin. Immunother.</italic></source><volume>13</volume><fpage>1615</fpage>&#8211;<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmid">28277821</pub-id><pub-id pub-id-type="pmcid">PMC5512770</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume><fpage>1</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02002-2017</pub-id><pub-id pub-id-type="pmcid">PMC5923077</pub-id><pub-id pub-id-type="pmid">29514901</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Evaluation of candidate vaccine approaches for MERS-CoV.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>6</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic toggle="yes">in vitro</italic>.</article-title><source><italic toggle="yes">Cell Res.</italic></source><volume>30</volume><fpage>269</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-280</pub-id><pub-id pub-id-type="pmid">32020029</pub-id><pub-id pub-id-type="pmcid">PMC7054408</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD.</article-title><source><italic toggle="yes">Cell Rep.</italic></source><volume>28</volume><fpage>3395.e6</fpage>&#8211;<lpage>3405.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.052</pub-id><pub-id pub-id-type="pmid">31553909</pub-id><pub-id pub-id-type="pmcid">PMC6935267</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome.</article-title><source><italic toggle="yes">Clin. Infect. Dis.</italic></source><volume>39</volume><fpage>1071</fpage>&#8211;<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.1086/423808</pub-id><pub-id pub-id-type="pmid">15472864</pub-id><pub-id pub-id-type="pmcid">PMC7107918</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warimwe</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Gesharisha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>B. V.</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Otingah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>6</volume><fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/srep20617</pub-id><pub-id pub-id-type="pmid">26847478</pub-id><pub-id pub-id-type="pmcid">PMC4742904</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Fusion of enveloped viruses in endosomes.</article-title><source><italic toggle="yes">Traffic</italic></source><volume>17</volume><fpage>593</fpage>&#8211;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1111/tra.12389</pub-id><pub-id pub-id-type="pmid">26935856</pub-id><pub-id pub-id-type="pmcid">PMC4866878</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widagdo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N. M. A.</given-names></name><name name-style="western"><surname>Stalin Raj</surname><given-names>V.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name></person-group> (<year>2017</year>). <article-title>MERS-coronavirus: from discovery to intervention.</article-title><source><italic toggle="yes">One Heal.</italic></source><volume>3</volume><fpage>11</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.onehlt.2016.12.001</pub-id><pub-id pub-id-type="pmid">28616497</pub-id><pub-id pub-id-type="pmcid">PMC5454172</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirblich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Bernbaum</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>One-health: a safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>91</volume><fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02040-16</pub-id><pub-id pub-id-type="pmcid">PMC5215356</pub-id><pub-id pub-id-type="pmid">27807241</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S. K. P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Coronavirus diversity, phylogeny and interspecies jumping.</article-title><source><italic toggle="yes">Exp. Biol. Med.</italic></source><volume>234</volume><fpage>1117</fpage>&#8211;<lpage>1127</lpage>. <pub-id pub-id-type="doi">10.3181/0903-MR-94</pub-id><pub-id pub-id-type="pmid">19546349</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S. K. P.</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>R. W. S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>192</volume><fpage>1898</fpage>&#8211;<lpage>1907</lpage>. <pub-id pub-id-type="doi">10.1086/497151</pub-id><pub-id pub-id-type="pmid">16267760</pub-id><pub-id pub-id-type="pmcid">PMC7110183</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="book"><collab>World Health Organization [WHO]</collab> (<year>2018</year>). <source><italic toggle="yes">WHO MERS Global Summary and Assessment of Risk.</italic></source><publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>.</mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.</article-title><source><italic toggle="yes">Science</italic></source><volume>1263</volume><fpage>1260</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Jan</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Juan</surname><given-names>H. F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y. S. E.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Small molecules targeting severe acute respiratory syndrome human coronavirus.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>101</volume><fpage>10012</fpage>&#8211;<lpage>10017</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403596101</pub-id><pub-id pub-id-type="pmid">15226499</pub-id><pub-id pub-id-type="pmcid">PMC454157</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C. T. K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.</article-title><source><italic toggle="yes">Sci. Adv.</italic></source><volume>5</volume>:<issue>eaav4580</issue>. <pub-id pub-id-type="doi">10.1126/sciadv.aav4580</pub-id><pub-id pub-id-type="pmid">30989115</pub-id><pub-id pub-id-type="pmcid">PMC6457931</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Antibodies and vaccines against Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Emerg. Microbes Infect.</italic></source><volume>8</volume><fpage>841</fpage>&#8211;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2019.1624482</pub-id><pub-id pub-id-type="pmid">31169078</pub-id><pub-id pub-id-type="pmcid">PMC6567157</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W. P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.</article-title><source><italic toggle="yes">Nature</italic></source><volume>428</volume><fpage>561</fpage>&#8211;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1038/nature02463</pub-id><pub-id pub-id-type="pmid">15024391</pub-id><pub-id pub-id-type="pmcid">PMC7095382</pub-id></mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C. C. Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Exceptionally potent neutralization of middle east respiratory syndrome coronavirus by human monoclonal antibodies.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>88</volume><fpage>7796</fpage>&#8211;<lpage>7805</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00912-914</pub-id><pub-id pub-id-type="pmid">24789777</pub-id><pub-id pub-id-type="pmcid">PMC4097770</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>6</volume>:<issue>8223</issue>. <pub-id pub-id-type="doi">10.1038/ncomms9223</pub-id><pub-id pub-id-type="pmid">26370782</pub-id><pub-id pub-id-type="pmcid">PMC4571279</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yong</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus.</article-title><source><italic toggle="yes">Front. Microbiol.</italic></source><volume>10</volume>:<issue>1781</issue><pub-id pub-id-type="doi">10.3389/fmicb.2019.01781</pub-id><pub-id pub-id-type="pmcid">PMC6688523</pub-id><pub-id pub-id-type="pmid">31428074</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Toots</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Ludeke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luczo</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses.</article-title><source><italic toggle="yes">Antimicrob. Agents Chemother.</italic></source><volume>62</volume><fpage>1</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00766-718</pub-id><pub-id pub-id-type="pmcid">PMC6105843</pub-id><pub-id pub-id-type="pmid">29891600</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J. F. W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z. W.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>10</volume>:<issue>120</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-08015-x</pub-id><pub-id pub-id-type="pmid">30631056</pub-id><pub-id pub-id-type="pmcid">PMC6328544</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>8</volume>:<issue>15092</issue>. <pub-id pub-id-type="doi">10.1038/ncomms15092</pub-id><pub-id pub-id-type="pmid">28393837</pub-id><pub-id pub-id-type="pmcid">PMC5394239</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seiler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kotin</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Fulgeras</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>74</volume><fpage>3852</fpage>&#8211;<lpage>3858</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.74.8.3852-3858.2000</pub-id><pub-id pub-id-type="pmid">10729159</pub-id><pub-id pub-id-type="pmcid">PMC111893</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Advances in mRNA vaccines for infectious diseases.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>10</volume>:<issue>594</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Cell. Mol. Immunol.</italic></source><volume>13</volume><fpage>180</fpage>&#8211;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Current advancements and potential strategies in the development of MERS-CoV vaccines.</article-title><source><italic toggle="yes">Expert Rev. Vaccines</italic></source><volume>13</volume><fpage>761</fpage>&#8211;<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2014.912134</pub-id><pub-id pub-id-type="pmid">24766432</pub-id><pub-id pub-id-type="pmcid">PMC4241375</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>92</volume>:<issue>e00837-18</issue><pub-id pub-id-type="doi">10.1128/JVI.00837-818</pub-id><pub-id pub-id-type="pmcid">PMC6146697</pub-id><pub-id pub-id-type="pmid">29950421</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alshukairi</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Baharoon</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Bokhari</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Nehdi</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses.</article-title><source><italic toggle="yes">Sci. Immunol.</italic></source><volume>5393</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.aan5393</pub-id><pub-id pub-id-type="pmcid">PMC5576145</pub-id><pub-id pub-id-type="pmid">28778905</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R. A. P. M.</given-names></name><name name-style="western"><surname>Kayali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Passive immunotherapy with dromedary immune serum in an experimental animal model for middle east respiratory syndrome.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>89</volume><fpage>6117</fpage>&#8211;<lpage>6120</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00446-415</pub-id><pub-id pub-id-type="pmid">25787284</pub-id><pub-id pub-id-type="pmcid">PMC4442417</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice ?.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>84</volume><fpage>9318</fpage>&#8211;<lpage>9325</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01049-1010</pub-id><pub-id pub-id-type="pmid">20610717</pub-id><pub-id pub-id-type="pmcid">PMC2937604</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J. J. J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J. J. J.</given-names></name><name name-style="western"><surname>Mangalam</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses.</article-title><source><italic toggle="yes">Immunity</italic></source><volume>44</volume><fpage>1379</fpage>&#8211;<lpage>1391</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id><pub-id pub-id-type="pmid">27287409</pub-id><pub-id pub-id-type="pmcid">PMC4917442</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin.</article-title><source><italic toggle="yes">Nature</italic></source><volume>579</volume><fpage>270</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-2017</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chakraborti</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>104</volume><fpage>12123</fpage>&#8211;<lpage>12128</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0701000104</pub-id><pub-id pub-id-type="pmid">17620608</pub-id><pub-id pub-id-type="pmcid">PMC1924550</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Gorbalenya</surname><given-names>A. E.</given-names></name></person-group> (<year>2000</year>). <article-title>Virus-encoded proteinases and proteolytic processing in the nidovirales.</article-title><source><italic toggle="yes">J. Gen. Virol.</italic></source><volume>81(Pt 4)</volume>, <fpage>853</fpage>&#8211;<lpage>879</lpage>.<pub-id pub-id-type="pmid">10725411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-81-4-853</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J. F. W. W.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D. S. C. C.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2016a</year>). <article-title>Coronaviruses-drug discovery and therapeutic options.</article-title><source><italic toggle="yes">Nat. Rev. Drug Discov.</italic></source><volume>15</volume><fpage>327</fpage>&#8211;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id><pub-id pub-id-type="pmid">26868298</pub-id><pub-id pub-id-type="pmcid">PMC7097181</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>To</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Middle east respiratory syndrome HHS public access.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>386</volume><fpage>995</fpage>&#8211;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60454-60458</pub-id><pub-id pub-id-type="pmid">26049252</pub-id><pub-id pub-id-type="pmcid">PMC4721578</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>S. H. E.</given-names></name><name name-style="western"><surname>Rustomjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mwaba</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2016b</year>). <article-title>Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>16</volume><fpage>e47</fpage>&#8211;<lpage>e63</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)00078-75</pub-id><pub-id pub-id-type="pmid">27036359</pub-id><pub-id pub-id-type="pmcid">PMC7164794</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>